

ISSUED TO M/s. _____

S.No.....

NOT TRANSFERABLE



TENDER NO. :- BPPI/DRUG- 016/2015

**TENDER FOR SUPPLY OF DRUGS &
MEDICINES**

TO

**Bureau of Pharma Public Sector Undertakings of
India (BPPI)**

For the year 2015-17



**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF
INDIA**

(Set up under the Department of Pharmaceuticals, Govt. of India)

IDPL corporate office Complex, Old-Delhi-Gurgaon Road, Dundaheera, Gurgaon 122016(HR)

Telephone: 0124-4303751 / 4556754; Fax: 0124-230370; Website: janaushadhi.gov.in

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)

(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)

Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003

Working Office: IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHARA, GURGAON (HR)

Telephone: **0124-4556751/56**; Fax: **0124-2340370** Website: **janaushadhi.gov.in**

**TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO
BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF
INDIA FOR THE YEAR 2015-2017**

Tender Reference	:BPPI/DRUG-016/2015 Dt. 28/01/2015
Date of commencement of Sale of tender documents	:28/01/2015(Wednesday)
Last date for sale of tender documents	: 20/02-2015 (Friday)
Time and date and place pre-bid meeting	:11:00 AM on 13/02/2015 (Friday) Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office, IDPL Complex, Old-Delhi -Gurgaon Road, Dundahera, Gurgaon-122016 (Haryana)
Last date and time for receipt of tender documents	:02/03/2015 upto 12:00 Noon
Time and date of opening of tender	:12:30 PM on 02/03/2015 (Monday)

Place of opening of tender

: Bureau of Pharma Public Sector
Undertakings of India,

IDPL corporate office, IDPL
Complex, Old-Delhi -Gurgaon
Road, Dundahera, Gurgaon-
122016 (Haryana)

Address for Communication:

Bureau of Pharma Public Sector
Undertakings of India,

IDPL corporate office, IDPL
Complex, Old-Delhi -Gurgaon
Road, Dundahera, Gurgaon-
122016 (Haryana)

Cost of the Tender Document

Rs. 2,250/- (Inclusive of Tax)

Contact Person for clarification if any:

1. Sh. K Chopra, Director (Operations),

0124-4040759, M - 9711003043

Email: kchopra.bppi@gmail.com

2. Sh. Mahadev Agarwal,

Manager (Regulatory),

0124-4556756, M - 9873294473

Email: mahadevpharm.bppi@gmail.com

Alternatively, the tender document can be downloaded from the website of BPPI: janaushadhi.gov.in and pharmaceuticals.gov.in. However the cost of tender form needs to be paid by way of demand draft drawn in any nationalized bank in favor of “Bureau of Pharma public sector undertakings of India “payable at Gurgaon/Delhi along with tender document at the time of submission.

TABLE OF CONTENTS

Sl.No.	Description	Page No.
1.	Last Date for receipt of Tender	08
2.	Eligibility Criteria	08
3.	General Conditions	09
4.	Technical Bid – Cover “A”	10
5.	Price Bid – Cover “B”	13
6.	Opening of Cover “A” and Cover “B” of Tender	14
7.	Earnest Money Deposit	15
8.	Other Conditions	15
9.	Acceptance of Tender	17
10.	Security Deposit and Agreement	18
11.	Methodology for placing orders	19
12.	Supply Conditions	21
13.	Logograms	23
14.	Packing	23
15.	Quality Testing	25
16.	Payment Provisions	26
17.	Handling & Testing Charges	27
18.	Liquidated Damages and other penalties	27
19.	Deduction and other penalties on account of Quality failure	28
20.	Blacklisting in the event of withdrawal from the tender, and Non-Adherence to the Quality Standards and supply schedule	29
21.	Saving Clause	32
22.	Resolution of Disputes	33

23.	Appeal	33
24.	Contacting the Purchaser by the Bidder	33
25.	Fraudulent and Corrupt Practices	34
26.	Jurisdiction	36
27.	Annexure-I (Sales Tax Clearance Certificate)	37
28.	Annexure-II (Declaration for logogram)	39
29.	Annexure-III (Declaration for acceptance of tender conditions and compliance of GMP)	46
30.	Annexure-IV (Declaration for eligibility in participating the tender)	55
31.	Annexure-V (Details of EMD submitted)	56
32.	Annexure-VI (Notarized Under taking)	57
33.	Annexure-VII (Proforma for Performance Certificate)	58
34.	Annexure-VIII (Annual Turnover Statement)	59
35.	Annexure-IX (Details of requirements for Drugs and Medicines)	60
36.	Annexure-X (Packing Specifications)	75
37.	Annexure-XI (Agreement format)	78
38.	Annexure-XII (Performance Security Bank Guarantee)	81
39.	Annexure-XIII (Details of Manufacturing Unit)	82
40.	Annexure-XIV (List of Items quoted)	84
41.	Annexure-XV (Mandate Form for RTGS)	85
42.	Annexure-XVI (Check List)	87

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF

PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

FOR THE YEAR 2015-17

Jan Aushadhi Campaign was started in 2008 with key objective of making quality generic medicines available at affordable prices for all, particularly the poor and disadvantaged, through specialized outlets called Jan Aushadhi Stores (JAS). In order to enable a focused and institutional approach to implement the Jan Aushadhi Campaign in particular, BPPI was established in December, 2008 under the Department of Pharmaceuticals, Government of India, with the support of all the CPSUs.

The Bureau has been registered as an independent society under the Societies Registration Act, 1860, in April, 2010. BPPI follows the provisions of GFR, 2005 as amended from time to time, the CVC guidelines, and instructions from the Department of Pharmaceuticals.

After varied success in last five years and to give a new thrust to Jan Aushadhi Campaign, a New Business Plan has been worked out. It aims to extend the geographical coverage of the scheme, by opening more than 3000 stores during the 12th Plan Period. It is proposed to channelize efforts to popularize the scheme in a few selected states and ensure availability of the complete basket of medicines at affordable prices.

Tender Inviting Authority – Director (Operations), Bureau of Pharma Public Sector Undertakings of India, IDPL Corporate Office, IDPL Complex, Old-Delhi-Gurgaon Road, Dundaheera, Gurgaon -122016 (Haryana) (hereinafter referred as **Tender Inviting Authority** unless the context otherwise requires).

Tender Accepting Authority – CEO, Bureau of Pharma Public Sector Undertakings of India, (hereinafter referred as **BPPI** unless the context otherwise requires)

Tender Inviting Authority invites **Tender for the supply of Drugs and Medicines to BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, for the year 2015-2017.**

1. LAST DATE FOR RECEIPT OF TENDERS.

(a) Sealed Tenders [in two separate covers {Technical bid (Cover “A”) and price bid Price Bid (Cover “B”)}] will be received till **12:00 Noon upto 02/03/2015(Monday)** by the Tender Inviting Authority, Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office, IDPL complex, Old-Delhi-Gurgaon Road, Dundaheera, Gurgaon -122016 (Haryana) for the year 2015-17.

(b) The price bid shall be valid for a period of 120 days from the date of opening of Cover-A (Technical Bid) and prior to the expiry of the bid validity. The Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit. However, BPPI reserves the right to place purchase orders at the quoted rate till such period.

2. ELIGIBILITY CRITERIA

(a) Tenderer shall be a manufacturer having valid own drug manufacturing unit duly licensed by licensing authorities with valid GMP certificate or direct importer holding valid import license. Distributors/Suppliers/Agents/Loan licensees are not eligible to participate in the Tenders.

(b) Average Annual turnover in the last three years i.e. 2011-2012, 2012-2013 and 2013-14 shall not be less than **Rs. 20 Crores.**

(c) Tender should not be submitted for the product(s) for which the firm / company has been blacklisted by any State Government / Central Government / its Drug procurement agencies due to quality failure of the drugs supplied in last 3 years.

(d) The Company/Firm which has been blacklisted by any State Government/Central Government / its Drug procurement agencies due to quality failure of the drugs supplied should not participate in the tender during the period of blacklisting for last 3 years.

(e) (i) The Tenderer should give a notarized affidavit that they have not been black listed due to quality failure for the quoted product /firm by any State Government / Central Government / its Drug procurement agencies. (Notarized affidavit as per **Annexure-IV**) for last 3 years.

(ii) During the validity of the tender if the firm / Company is blacklisted by any State Government / Central Government / its Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI by the tenderer firm/ company within one month.

3. GENERAL CONDITIONS.

(i) A complete set of tender documents may be purchased by any interested eligible person by making an application in writing and upon payment of a non refundable fee as indicated in the advertisement in the form of Demand draft drawn in favor of **BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA** payable at Gurgaon/Delhi.

(ii) Alternatively, the tender document can be downloaded from the websites janaushadhi.gov.in and pharmaceuticals.gov.in. However the cost of tender form needs to be paid by way of demand draft drawn in any nationalized bank in favor of “Bureau of Pharma Public Sector Undertakings of India” payable at Gurgaon/Delhi along with the tender.

(iii) Tender document may be purchased from the office of Tender Inviting Authority between 10-00 AM to 5-00 PM on or before **20/02/2015(Friday)** on all working days either in person or by post. Tender Inviting Authority will not be responsible in any way for postal delay.

(iv) All tenders must be accompanied with Earnest Money Deposit as specified in Clause 7 of the Tender document.

(v) Tenders will be opened in the presence of Tenderers/authorized representatives who choose to attend on the specified date and time.

(vi) (a) At any time prior to the last date of submission of Tender, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by an amendment. All the prospective Tenderers who have purchased the tender document will be notified of the amendment in writing and that will be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of tenders.

(b) Any person who has downloaded the tender document should watch for amendment, if any, on the website janaushadhi.gov.in and pharmaceuticals.gov.in for which BPPI will not issue any separate communication to them.

(vii) Interested eligible Tenderers may obtain further information in this regard from the office of the Tender Inviting Authority on all working days between 10:00 AM and 5:00 PM.

(viii) Certain products are reserved for purchase from Central Public Sector Undertakings (CPSU's). Orders for these items will be first placed with CPSU's.

4. TECHNICAL BID - COVER "A"

4.1. The Tenderer should furnish the following documents in a separate cover hereafter called "**Cover A**". (All the documents submitted should be signed and sealed by the Tenderer in each page and photocopies of the documents should be attested by the Tenderer. All documents should also be notarized in each page)

(a) Earnest Money Deposit, shall be as indicated in Clause 7 of the tender document in the form of **Bankers Cheque or Demand Draft** favoring "Bureau of Pharma Public Sector Undertakings of India " , payable at Gurgaon/Delhi . EMD in any other form like *cheque/cash/postal order* etc. will not be accepted.

(b) Documentary evidence for the constitution of the Company/Firm such as Memorandum and Articles of Association, Partnership deed, Permanent Registration Number etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor. The list of present Directors in the Board of the Company duly certified by a Company Secretary of the Company/Practicing Company Secretary / Chartered Accountant to be furnished.

(c) The Tenderer should furnish self attested photocopy of valid drug Manufacturing Licence for the product, duly approved by the Licensing Authority for each and every product quoted as per specification in the tender. The licence must have been duly renewed up to date and the items quoted shall be clearly highlighted in the licence. Original documents should be produced for verification when demanded. However, if renewal application for manufacturing licence has been filed, copy of same duly receipted by drug authorities must be enclosed along with the validity certificate from state licencing authority (SLA)

(d) Self attested photocopy of import license (in Form 10 with Form 41), as per Rule 122A of the Drugs and Cosmetics Act 1940, if the product is imported should be furnished. The licence must have been renewed up to date. A copy of a valid licence for the sale of Drugs imported by the firms issued by the State Licensing Authority shall be enclosed. Original documents should be produced for verification when demanded.

(e) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Tenderer should be enclosed with the tender duly signed by the Authorized signatory of the Company/Firm and such authorized officer of the Tenderer should sign the tender documents.

(f) Authorization letter nominating an officer of the Tenderer to transact the business with the BPPI to be furnished.

(g) Market Standing Certificate issued by the state Licensing Authority as a Manufacturer for each product quoted in the tender for a minimum 3 years (Certificate should be enclosed with list of items). In case of direct importer, evidence for importing the said items such as bill of landing, bill of entry and certificate of analysis are to be produced.

(h) Performance statement of manufacture/import to establish market standing as per format in **Annexure-VII**.

(i) Non-conviction Certificate issued by the licensing authority of the State certifying that the firm/company has not been convicted. The certificate should not be more than 6 months old at the time of submission of technical bid.

(j) Valid Good Manufacturing Practices Certificate (GMP) as per Schedule-‘M’ (for manufacturers only) issued by the Licensing Authority. The Tenderer shall also furnish a notarized declaration in the format given in **Annexure-III** declaring that the Tenderer complies with the requirements of GMP (as per **Schedule-‘M’**). In case of Imported drugs, labels and product literature of all quoted product(s) must be submitted with WHO-GMP/certificate which is at par with WHO-GMP issued by exporting countries like U.S. FDA etc/COPP certificate of their Principal Manufacturing company/firm.

(k) Annual turnover statement for 3 years i.e., 2011-12, 2012-13 and 2013-14 should be furnished in the format given in **Annexure-VIII** duly certified by the chartered Accountant.

(l) Copies of the Annual reports including the Balance Sheet and Profit and Loss Account for the last three years i.e. 2011-12, 2012-13 and 2013-14 duly certified by the Chartered Accountant.

(m) a. Sales Tax Clearance certificate as on 31.03.2014 (as per form attached in **Annexure-I**).

b. Latest Income tax assessment orders/returns filed are to be attached.

(n) (i) Undertaking (as in the proforma given in **Annexure-II**) for embossment of logo on strip of tablets, capsules, on labels of vials, Ampoules, bottles, tubes etc. as the case may be, and for supply of tablets/capsules in strips as per conditions specified under Clause 13 herein, notarized by the Notary Public.

(ii) Undertaking (as in the proforma given in **Annexure-II (A)**) for affixing the Jan Aushadhi logo on the Secondary/Primary packing for the imported items along with Brand/Trade names.

(o) The details containing the name and address of the manufacturing premises / importing unit where the items quoted are actually manufactured should be given as per the format in **Annexure-XIII** along with exact address of registered/Corporate office.

(p) Documents, if any, to show that the manufacturing unit/importer has been recognized by any other Indian / International Standard Organizations etc. as applicable.

(q) Details of technical personnel employed in the manufacturing and testing of drugs (Employee Name, Qualification, and Experience) as endorsed in license.

(r) List of items quoted (The name & Drug code of the Items quoted should be Furnished and **the rate of those items should not be indicated in this list**), as shown in the **Annexure-XIV** should be given in duplicate.

(s) A Checklist (Annexure- XVI) indicating the documents submitted with the tender document and their respective page number shall be enclosed with the tender document. The documents should be serially arranged as per this **Annexure-XVI** and should be securely tied or bound. If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but necessary document regarding separate manufacturing units will be submitted as a separate set with the same tender. However one bidder will be allowed to submit only one offer for one product.

(t) The tender document should be signed by the authorized official of the Tenderer in all pages with office seal.

(u) All the documents enclosed with the tender document should also be signed by the authorized official of the Tenderer.

4.2. The all documents indicated above should be kept and sealed in a separate Cover Superscribed as "TECHNICAL BID - COVER "A" – TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA FOR THE YEAR 2015-2017 DUE ON **02/03/2015 AT** 12:00 NOON. AND ADDRESSED TO THE TENDER INVITING AUTHOURITY, BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA ,IDPL CORPORATE OFFICE, IDPL COMPLEX, OLD – DELHI- GURGAON ROAD, DUNDAHERA, GURGAON- 122016 (HARYANA).

5. PRICE BID - COVER "B"

5.1. Cover "B" contains the Price Bid of the Tenderer.

(i) Bid should be typewritten and every correction and interlineations in the bid should be attested with full signature by the Tenderer, failing which the bid will be treated as ineligible. Corrections done with correction fluid will not be accepted.

(ii) Each page of the price bid should be duly signed by the Tenderer affixing the office seal.

(iii) (a) The Tenderer shall fill in the rate in the **Annexure-XVII** and **Annexure-XVIII** for the items quoted and also in excel sheets (supplied with tender document) and such filled in **Annexure-XVII** and **Annexure-XVIII** in soft copy should be submitted in pen drive or compact disc (CD).

(b) The Tenderers who have downloaded Tender document shall also download excel files of Annexure XVII and Annexure-XVIII and soft copies of such filled in **Annexure-XVII** and **Annexure-XVIII** should be submitted in pen drive or compact disc.

(iv) **Determination of L1 bidder:** In determining the lowest evaluated price, the rate quoted per unit landed price as indicated in column No. 6 of the **Annexure-XVII** shall be taken into consideration.

(v) The rate quoted in column 6 of **Annexure-XVII** should be for a unit and for the given specification. **The rates quoted in paisa are to be in 2 digits.** The Tenderer is not permitted to change/alter specification or unit size given in the **Annexure XVII**.

(vi) The Tenderer is required to furnish the break up details of landed price in **Annexure-XVIII**.

(vii) The rate quoted in column 6 of **Annexure-XVII** and in column 7 of **Annexure-XVIII** should be one and the same.

(viii) The details of products rates and manufacturing capacity (for each item individually) given in **Annexure-XVII** should be entered clearly given along with the tender.

(ix) The bidder shall specifically mention **“EXEMPTED”** when the item is excisable but exempted for the time being, based on turn over or for any other grounds by the notification issued by the Government of India (**Also refer clause 16.6a**).

(x) The bidder, who has quoted excise duty as **“NIL” in ANNEXURE-XVIII** and the item is excisable, at award of contract, will be eligible for payment of excise duty only on production of invoices drawn as per Central Excise Rules.

5.2. The Tenderers shall submit duly signed **Annexure-XVII** and **Annexure- XVIII** in a sealed cover Super scribed as **“PRICE BID COVER “B” –**

TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BPPI FOR THE YEAR 2015-2017”.

The "Cover-B" should also be addressed to the **TENDER INVITING AUTHORITY, BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, IDPL CORPORATE OFFICE, IDPL COMPLEX, OLD- DELHI- GURGAON ROAD, DUNDAHERA, GURGAON-122016(HARYANA)**

5.3. Two sealed covers {Technical bid (Cover “A”) {Refer Clause No.4.2} and Price Bid (Cover “B”)} {Refer clause 5.(2) } shall be placed in a separate cover which shall be sealed and Superscribed as

“TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO “BPPI” FOR THE YEAR 2015-2017 DUE ON 02/03/2015 AT 12.00 NOON and addressed to the

TENDER INVITING AUHORITY, BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, IDPL CORPORATE OFFICE, IDPL COMPLEX, OLD- DELHI- GURGAON ROAD, DUNDAHERA, GURGAON-122016(HARYANA), which shall be submitted within the date and time as specified in Clause 1(a).

5.4. If the last date for submission of Tender is declared holiday, the tenders may be submitted on the next working day upto 12.00 A.M.

6. OPENING OF COVER “A” AND COVER “B” OF TENDER

6.1 Only authorized official as indicated in Clause 4.1. (f) are entitled to be present at the time of opening of Technical Bid - Cover “A” of the tender submitted by them.

6.2 Tenderers, who are found eligible on satisfying the criteria for technical evaluation and inspection, will only be invited to be present at the time of opening of Price Bid - Cover “B” of the tender.

7. EARNEST MONEY DEPOSIT

7.1. The Earnest Money Deposit referred to under Clause 3(iv) & 4.1(a), shall be **Rs. 1 lakh. The Earnest Money Deposit shall be paid in the form of Bankers Cheque or Demand Draft in favor of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, payable at Gurgaon/Delhi.**

7.2.(i) The tender submitted without sufficient EMD will be summarily rejected.

(ii) The Earnest Money Deposit will be refunded to the successful bidders within 30 days from the date of signing the contract agreement and on the deposit of Security Deposit.

(iii) The Earnest Money Deposit (EMD) of the unsuccessful bidders will be returned within 7 days after finalization of tender.

(iv) The Earnest Money Deposit (EMD) will be forfeited, if the tenderer withdraws his bid any time after opening of price bid / non execution of agreement /undertaking within the period prescribed.

(v) The Earnest Money Deposit (EMD) will be forfeited, in case of the lowest bidder, fails to execute the contract agreement and / or deposit the security Deposit within the stipulated time.

(vi) Tenderer may be exempted from the payment of EMD, provided that requisite certificate from NSIC is produced.

(vii) State PSUs are exempted from the payment of EMD.

8. OTHER CONDITIONS

8.1.(i) The details of the required drugs, medicines, etc., are shown in **Annexure-IX. *The tender quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased*** by the BPPI, at its discretion, depending on it is actual need. Though the tentative quantity is indicated in the agreement, the BPPI, will confirm the actual requirement then / there through purchase order/orders. The tenderers shall supply the drugs only on the basis of the purchase order issued by the BPPI. Any supply without a valid purchase order will not be acceptable by BPPI and the BPPI shall not be responsible for any loss on this account.

(ii) However, once the purchase order/orders is/are issued by the BPPI, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the agreement / undertaking.

(iii) The rates quoted shall not be varied with the order quantity or the destination during the full contract period.

8.2. Tender has been called for in the **generic name of drugs**. The Tenderers should quote the rates for the generic products only. The composition, strength and packing of each product should be as per specifications given in **Annexure-IX**. Any variation, if found, will result in rejection of the tender. However the imported/combination drugs are allowed to quote in trade / brand name.

8.3. Rates (inclusive of Customs duty, transportation, insurance, and any incidental charges, but exclusive of CST/VAT (Sales Tax) and excise duty) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like “AT CURRENT MARKET RATES” shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.

8.4. Each bid must contain not only the unit rate but also the total value of each item quoted for supply in the respective columns. The aggregate value of all the items quoted in the tender shall also be furnished.

8.5. The price quoted by the tenderers shall not, in any case exceed the DPCO controlled price, if any, fixed by the Central/State Government, the Maximum Retail Price (MRP) and the selling price of the tenderer. Tender Inviting Authority at its discretion, may exercise, the right to revise the price at any stage so as to conform to the controlled price or MRP or the selling price of the tenderer as the case may be. This discretion will be exercised without prejudice to any other action that may be taken against the Tenderer.

8.6. The rates quoted and accepted will be binding on the Tenderer for the full contract period of two years and any increase in the price will not be entertained till the completion of this contract period. Accordingly this clause will be applicable for all orders placed during the contract period.

8.7. No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as “SUBJECT TO AVAILABILITY”, “SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED” etc., will not be entertained under any

circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

8.8. Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.

8.9. The Tenderer shall allow inspection of the factory at any time after the opening of technical bid and during the entire contract period by a team of Experts/Officials nominated by the Tender Inviting Authority for the purpose. The Tenderer shall extend necessary cooperation to such team in inspection of the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If Company/Firm does not allow for any such inspection, their tenders will be rejected during the currency of the contract.

8.10 “MRP inclusive of all taxes” is to be printed on each unit/label. MRP will be intimated to successful bidders at the time of placing purchase orders.

9. ACCEPTANCE OF TENDER

9.1. Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done on the basis of rate per unit landed price as mentioned in column 6 of **Annexure-XVII** and column 7 of **Annexure-XVIII**. As per Central Vigilance Commission guidelines, negotiations will be done with L1 bidder only.

9.2. BPPI reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.

9.3. BPPI or its authorized representative(s) has the right to inspect the manufacturing premises of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections.

9.4. The acceptance of the tenders will be communicated to the lowest Tenderers in writing.

10. SECURITY DEPOSIT AND AGREEMENT

10.1 Security Deposit:

On being informed about the acceptance of the tender and at the time of signing the Agreement, the lowest Tenderer shall pay the Security Deposit @ 5% of the value of order in the form of ***Demand Draft or irrevocable Bank Guarantee*** in favor of Bureau of Public Sector Undertakings of India from any scheduled Bank . In case the Security Deposit is paid in form of Bank Guarantee, the bank guarantee shall be valid for a period beyond 3 months of the validity of the contract. The format of Bank Guarantee is at **Annexure-XII**.

10.2. The lowest Tenderer shall execute an agreement on a non- judicial stamp paper of value of Rs.100/- (stamp duty to be paid by the Tenderer) within 15 days from the date of the intimation from BPPI informing that his tender has been accepted. The Specimen form of agreement is available in **Annexure-XI**.

10.3. The Tenderer shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons what so ever.

10.4. All notices or communications relating to and arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Tenderer if delivered to him or left at the premises, places of business or abode as provided by the tenderer.

10.5. If the lowest Tenderer fails to execute the agreement and/or to deposit the required security deposit within the time specified or withdraws the tender, after the intimation of the acceptance of the tender or owing to any other reasons to undertake the contract, the contract will be cancelled and the Earnest Money Deposit deposited by the tenderer along with the tender shall stand forfeited by the BPPI and the firm will also be liable for all damages sustained by the BPPI apart from blacklisting and other penal actions.

10.6. The security deposit of supplier will be returned by BPPI only after the supplier has given undertaking to replace such medicines and indemnify BPPI against any losses on account of quality parameters.

11. METHODOLOGY FOR PLACING ORDERS

For the above purpose the following procedures will be adopted

(a) After the conclusion of Price Bid opening (Cover B), the rates offered by tenderers for each product are evaluated and lowest rate (L1 Rate) arrived at is declared and that tenderer is informed. As per CVC guidelines, negotiation can be held only with the L1 tenderer.

(b) The Tenderer, who has been declared as lowest tenderer for certain item(s), shall execute necessary agreement for the supply of the tendered quantity of such drugs/medicines as specified in the Tender Document on depositing the required amount as Performance Security and on execution of the agreement such Tenderer is eligible for the placement of Purchase Orders.

(c) If two or more than two Tenderer's are declared as lowest suppliers for the same item(s), such Tenderers shall execute necessary agreement as specified in the Tender Document on depositing the required amount as Performance Security and on execution of the agreement such Tenderer's are eligible for the placement of Purchase Orders for such item(s) for which they are declared as lowest. Placement of order shall be shared equally amongst these bidders.

(d) In the case of purchase of goods where the quantity offered at the lowest price is less than the total quantity required, the BPPI may, after placing orders with the lowest evaluated Tenderer for the entire quantity offered by such Tenderer subject to his ability to supply, require all the other eligible Tenderers who participated in the tender and offered a price higher than that offered by the lowest evaluated Tenderer, to submit sealed offers of the quantity they would be willing to supply at the price quoted by the lowest evaluated Tenderer, and thereafter place orders for the remaining required quantity with all those who match the lowest evaluated price such that those who bid lower prices in the original tender get a higher priority for supply.

(e) If the lowest supplier has failed to supply the required Drugs/Medicines within the stipulated time or within the extended time, as the case may be, BPPI will cancel such purchase orders and on cancellation, BPPI will place Purchase Orders with L2 (L3 if L2 also fails) or to the other tenderers at the risk and cost of the defaulted supplier, subject to the maximum production capacity, such Tenderer or other tenderers shall execute necessary agreement indicating the production capacity as specified in the Tender Document and deposit the required amount as Performance Security as the prior conditions to become eligible for placement of Purchase Orders for the item(s) quoted by them.

(f) If the supplier fails to supply the Drugs /Medicines for any of the three Purchase Orders placed, at any point of time, either fully or partly, within the stipulated time, BPPI is at liberty to place Purchase Orders with other Tenderers (in ascending order, viz., L2,L3 and so on) at the price offered by them and in such cases the supplier is liable to indemnify BPPI, WITH OUT ANY PROTEST OR DEMUR, for the difference in cost incurred by BPPI and the BPPI is entitled to recover the difference in cost from the amount due/payable to the supplier.

(g) Notwithstanding anything contained in para (f) above, the supplier, after committing the default in supply either partly or fully, can inform the BPPI about his willingness to execute the Purchase Order during the tender period. The BPPI at discretion may consider the willingness of the supplier on merit. However, such supplies will be subjected to the levy of Liquidated Damages, unexecuted fine and other penalties as stipulated in the tender document, agreement and purchase order.

(h) The supplier shall start supply of the Drugs/Medicines required by BPPI at Central Ware House (CWH), Gurgaon within the period stipulated.

(i) The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. BPPI will not be responsible for the loss to the supplier and will not entertain any demand/claim.

(j) The supplier shall supply the Drugs/Medicines at the CWH, Gurgaon along with copy of Purchase order, copy of test reports and 3 original copies of Invoice. No payment will be processed without test reports.

(k) The supplier shall take utmost care in supplying the quality Drugs/Medicines and ensure that the batch number mentioned in the packages of the Drugs/Medicines tally with the batch number mentioned in the Invoice produced to BPPI for payment. Also the supplier shall ensure the quantity relevant to the Batch Number of the Drugs/Medicines is mentioned in the invoice.

(l) It is the duty of the supplier to supply Drugs/Medicines at the CWH Gurgaon and supply shall conform to the conditions mentioned in the provisions of tender documents, viz., logo, nomenclature, specification etc.,

(m) Subject to para (l) above, BPPI will process the invoices submitted by the supplier and the payments against supply will be made, within 30 days from the date the Drugs/Medicines supplied has been declared of STANDARD QUALITY, by the Empanelled laboratory of BPPI subject to various terms and conditions of the tender.

(n) Subject to the conditions mentioned in the Purchase Order, Tender Document, Agreement executed by the supplier and here under, the Supplier is entitled for the payment against supply. In case of any discrepancy in levy of LD, Penalty, Unexecuted Fine, Short Passing of Bills, such discrepancy shall be intimated within 30 days from the date of receipt of payment, failing which BPPI will not entertain any claim thereafter.

(o) BPPI reserves the right to place upto 50% additional purchase order of the quantities as contracted.

12. SUPPLY CONDITIONS

12.1. Purchase orders will be issued to the Tenderer(s) at the discretion of the BPPI as per actual requirements. All the supplies shall be received at the central warehouse at Gurgaon.

12.2. Within 3 days from the receipt of purchase orders the Tenderer should inform BPPI through fax and mail the confirmation for the receipt of the purchase order.

12.3. The Tenderer should also fax and mail the details of supply dates as specified in Annexure, to BPPI within 7 days from the receipt of the purchase order.

12.4(a) The supplier shall complete the supply within 45 days from the date of purchase order at the destinations mentioned in the purchase order. If the above day happened to be a holiday for BPPI, the supply should be completed by 5.00 PM on the next working day. In case of Non- execution of the order, BPPI reserves the right to place purchase orders (partially/fully) on alternate source at the risk and cost of the default tenderer(s) without any notice/Information. If the Tenderer fails to execute the supply within the stipulated time (30/45 days), the BPPI is at liberty to make alternative arrangement for purchase of the items of drugs and medicines for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the BPPI has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 19.

(b) The supplier may continue the supply of unexecuted quantity after 45th day, however Liquidated Damages as specified in clause 18.1 and 18.2 of the tender conditions, will be levied on the quantity supplied after the 45th day. However no supplies will be normally accepted after 5 PM of 75th day from the date of issue of the purchase order.

(c) For the first delivery, the supplier must supply the ordered quantity within 60 days for non-sterile products and 75 days for sterile products, from the date of Purchase Order.

12.5. Supplier shall complete the earliest pending purchase order before commencing the supply of subsequent purchase orders.

12.6. The supplied medicines and Drugs (covered in SCHEDULE “P” of Drugs and Cosmetics Act) should have the prescribed potency throughout the shelf life period as

prescribed in the Drugs and Cosmetics Act 1940 and rules there under and in relevant Pharmacopoeias.

12.7. The Tenderer must submit an Analysis report for every batch of drug along with invoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will be returned back to the suppliers and he is bound to replenish the same with Govt. approved lab test report. The Drugs and medicines supplied by the successful Tenderer shall be of the best quality and shall comply with the specifications, stipulations and conditions specified in the tender.

12.8. Tenderer should supply the product, within 2 months from the date of manufacture of that product. Products beyond 2 months from the date of manufacture shall not be accepted. For example product having manufacturing of April 2015 must be supplied before June 30, 2015.

12.9. The order stands cancelled at the end of 75th day from the issue of the purchase order after levying penalty on the value of unexecuted order as specified under Clause 18.3. Further, the Tenderer shall also be liable to pay other penalties as specified under Clauses 19. Security Deposit of such suppliers shall also be forfeited. However if such default occurs for 3 or more purchase orders penal action like blacklisting from participating in present and future tenders of BPPI shall be enforced by the BPPI

12.10. If at any time the Tenderer has, in the opinion of the BPPI delayed the supply of drugs due to one or more reasons related to Force Majeure events such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the BPPI at discretion for such period as may be considered reasonable. However such extension shall be considered only if a specific written request is made by the Tenderer within 10 days from the date of occurrence of such event with necessary documentary evidence. The exceptional events does not include the Scarcity of raw material, Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.

12.11. The supplier shall not be liable to pay LD and forfeiture of security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

13. LOGOGRAMS

Logogram means, wherever the context occurs, the design as specified in **Annexure-II. The name of the drug shall be mentioned in English and Hindi.**

13.1. Tenders for the supply for Drugs and medicines etc., shall be considered only if the Tenderer gives an undertaking that the product(s) will be prepared as per the specifications such as strength, minimum size and packed with appropriate size of the strips/blisters/bottles/tubes etc as per the design enclosed as per **Annexures-II & II-A.**

13.2. All tablets and capsules have to be supplied in packing as specified in product list (Annexure ix) and shall also conform to Schedule P1 of the Drugs & Cosmetics Act & Rules 1945, wherever it applies. Affixing of stickers and rubber stamps shall not be accepted and supplies will be returned back at supplier's cost.

13.3. Vials, Ampoules (more or equal than 5 ml) and Bottles containing the items tendered for should also carry the printed Jan Aushadhi logogram of proportionate size.

13.4. Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of agreement / violation of tender conditions and action will be taken to blacklist the product and/or fine will be deducted from the amount payable as per condition in Clause 18.5. However if such failure continuous despite notice, will be viewed as a serious lapse.

Tenderers who are not willing to agree to conditions above will be summarily rejected.

14. PACKING

14.1. The drugs and medicines shall be supplied in the package specified in **Annexure-IX** and **Annexure-X** and the package shall carry the logograms of proportionate size specified in **Annexures-II, II -A.** Non affixing of logograms will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 18.5

14.2. The minimum size of each tablet should be 6.4 mm in diameter and the minimum size of the blister packing and strip packing should be 70mm x 30 mm and 50mm x 130mm respectively. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5.

14.3. The packing in each carton shall be strictly as per the specification mentioned in **Annexure-X.** The outer carton should be of white board with a minimum of 300 GSM with laminated packing for the strips, blisters, ointments, creams etc. and for ampoules and

vials should be with white board of 350 GSM. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5. Storage conditions must be indicated on outer label.

14.4. The cap of bottle preparations should not carry the name of the supplier.

14.5. The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intra Muscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.

14.6. It should be ensured that only first hand virgin packaging material of uniform size, including bottle and vial, is used for packing.

14.7. All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

14.8. Packing should be able to prevent damage or deterioration during transit.

14.9. In the event of items of drugs supplied found to be **not as per specifications in respect of their packing and logogram**, the BPPI is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 18.5.

14.10. Designs of packaging with the logograms shall be subject to approval by BPPI within 7 days of receipt of the same from the supplier, as per the specifications. In case of failure of BPPI to do so, the supplier may go ahead with the design as per the specification in Annexure ix and x.

15. QUALITY TESTING

15.1. Samples of supplies from each batch will be chosen at the point of receipt of supply or distribution/storage points for testing. The samples will be sent to different laboratories including Government Drugs Testing Laboratory for testing as decided by the BPPI Handling and testing charges will be deducted by BPPI for the above purpose, as specified in Clause 17.

15.2. The Drugs shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf life period of the drug. The samples will be drawn periodically throughout the shelf life period and if found “Not of Standard Quality”, the cost of entire batch paid will be recovered whether consumed fully/partially. Also action will be initiated for blacklisting as per clause No.19 irrespective of the period of supply. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be “Not of Standard Quality” or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.

15.3. In the event of the samples of Drugs and medicines supplied fails in quality tests or found to be not as per specifications, the BPPI is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 19.

15.4. The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the BPPI. In case of any complaint in the field, the B.M.R/B.P.R for the particular batch of the product(s) supplied shall be produced when demanded.

15.5. The products should conform to the standards of IP/BP/USP/EP/JP as the case may be. In case the product is not included in the any of the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs, respective Country’s Pharmacopial standards shall be acceptable (even if the product is official in IP).

15.6. The case of admixture of drugs will be treated as a violation of tender conditions and fine will be levied as per clause 19. If such lapses happens more than twice in a tender period such cases will be treated as “Misbranded Drugs”.

16. PAYMENT PROVISIONS

16.1. No advance payments towards costs of drugs, medicines etc., will be made to the Tenderer.

16.2. Payments towards the supply of drugs and medicines will be made within 60 days from the date of receipt of goods, strictly as per the tender terms and condition. The payment will be made either by means of a/c payee Cheque or through RTGS (Real Time Gross Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original (**Annexure-XV**) to make the payment through RTGS/Core Banking/NEFT and the change of Bank Account during the validity of the tender will not be entertained normally.

16.3. All bills/Invoices should be raised in triplicate and in the case of excisable Drugs and Medicines, the bills should be drawn as per Central Excise Rules in the name of Bureau of Pharma Public Sector Undertakings of India. IDPL Complex, Dundehera, Gurgaon 122016 or in the name of any other authority as may be designated.

16.4. (i) Payments for supply will be considered only after supply of minimum 50% of Drugs ordered in the individual Purchase Order PROVIDED reports of Standard Quality on samples testing are received from Government Analyst or Approved Laboratories of BPPI

(ii) However, in case of cancellation of a particular purchase order due to failure in delivery, payment for part supplies less than 50% of the purchase order quantity on the date of cancellation of the purchase order may be considered for release of payment subject to the following:

(a) If the Tenderer have supplied at least 50% of the quantity ordered in the subsequent purchase order within 60 days from the issue of such purchase order.

(b) If further purchase order is not placed with the supplier due to any reason, not attributable to the supplier, the amount eligible will be paid after 60 days from the date of last supply.

(c) The payment for part supply as mentioned above will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk and cost etc., as per the tender conditions.

16.5. If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself, the Tenderer shall be bound to inform the BPPI immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.

16.6.(a) In case of any increase or decrease in the taxes, such as excise duty, customs duty, sales tax, VAT etc., after the date of submission of tenders and during the tender period, such variation in the taxes will be to the account of the BPPI. For claiming the additional cost on account of the increase in taxes, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to BPPI from the concerned Excise authorities and also must claim the same in the invoice separately. However the basic price structure and the price of the Drugs approved under the tender shall not be altered. Similarly if there is any reduction in the taxes and statutory levies as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the basis of the reduced taxes/statutory levies without any change in the basic price or the price structure of the drugs approved under the tender.

Any increase or decrease in taxes and statutory levies will be considered based on the notification issued by the Government.

(b) In case of successful bidder enjoying excise duty exemption on any criteria of turnover, area based etc., such bidder will not be allowed to claim excise duty at a later point of time, during the tenure of contract, when the excise duty is chargeable on goods manufactured.

16.7. Form 'C' shall be provided by BPPI, wherever required. The tenderers should quote the concessional rate of CST applicable in their bids.

17. HANDLING & TESTING CHARGES:

In all supplies, 1.5% of the supply value shall be deducted towards handling & testing charges.

18. LIQUIDATED DAMAGES AND OTHER PENALTIES:

18.1. If the supply reaches the designated places or Central Warehouse between 5 PM of the 45th day and 5 PM of 75th day from the date of issue of the purchase order, a liquidated damages will be levied at 2% per week or part thereof, subject to maximum of 10% irrespective of the fact that whether the BPPI has suffered any damage/loss or not, on account of delay in effecting supply. If the 45th day happens to be a holiday the supply will be accepted on the next working day without any penalty.

18.2. If the supply is received in damaged condition, open delivery of the supplies shall be received, wherein it is possible to physically inspect the shipment. Damaged products shall not be accepted.

18.3. All the Tenderers are required to supply the product(s) with printed logogram of appropriate size on the strips, blisters, vials, ampoules & bottles and with prescribed packing specification. If there are any deviation in these Tender conditions, action will be taken to blacklist the product and/or a separate damages will be levied @ 5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.14.11 and 13.4.

19. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITY FAILURE:

19.1. If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the receipt of the letter from the BPPI. Such stock shall be taken back at the expense of the Tenderer. The BPPI has the right to destroy such “NOT OF STANDARD QUALITY DRUGS” if the Tenderer does not take back the goods within the stipulated time. The BPPI will arrange to destroy the “NOT OF STANDARD QUALITY DRUGS” after the expiry of 30 days mentioned above without further notice, and shall also collect demurrage charges calculated at the rate of 2% per week on the value of the drugs rejected till such time stipulated.

19.2. If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description or otherwise faulty or unfit for consumption, then the contract price or prices of total such batches supplied will be recovered from the Tenderer, if payment had already been made to him. In other words the Tenderer will not be entitled to any payment whatsoever for Items of drugs found to be of “NOT OF STANDARD QUALITY” whether consumed or not consumed and the Tender Inviting Authority is entitled to deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.

19.3. For the supply of Adulterated/Spurious/Misbranded drugs, as defined in the Drugs and Cosmetics Act, 1940, to BPPI, the firm/company shall be blacklisted by BPPI and no further supplies shall be accepted from the firm/company. The Tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of BPPI for supply of Drugs and Medicines for a period of 5 years from the date of blacklisting. In case of supply of NOT OF STANDARD QUALITY drug(s) to BPPI, the product shall be blacklisted by BPPI and no further supplies shall be accepted for the particular drug(s). The Tenderer shall also not be eligible to participate in tenders of BPPI for supply of such Drugs and Medicines for a period of 2 years from the date of blacklisting. In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Security deposit will also be forfeited without any intimation.

19.4. The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the BPPI. The BPPI reserves the right to cancel the purchase orders, if the source of supply is not furnished.

19.5. The decision of the BPPI or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding. In such cases, the BPPI will be at liberty to terminate, the contract either wholly or in part on 30 days notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Security deposit.

19.6. For contravention of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the BPPI, and the Tenderer shall be liable to pay for all losses sustained by the BPPI in consequence of the termination which may be recovered from the Tenderer, as per rules besides forfeiture of Security deposit.

19.7. Non performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years besides forfeiture of Security deposit.

19.8. In the event of making Alternative Purchase, as specified in Clause 12.4 (a), Clause 14.11 and in Clause 15.3 penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the BPPI in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Security Deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.

19.9. In all the above conditions, the decision of the BPPI shall be final and binding.

20. BLACK LISTING IN THE EVENT OF WITHDRAWAL FROM THE TENDER, AND NON-ADHERENCE TO THE QUALITY STANDARDS AND SUPPLY SCHEDULE

20.1. BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER

(a) If the Tenderer(s) fails to execute the agreement / to perform the obligations under the tender conditions / commits default in the performance of the contract, such Tenderers will be

blacklisted for a period of 2 years by BPPI from the date of observing the defect besides forfeiture of Security deposit.

BLACKLISTING FOR QUALITY FAILURE

20.2.1. Quality Test by the Empanelled Laboratories of BPPI

a. Each and every batch of drugs/medicines shall be subjected to quality test by the Empanelled laboratories.

b. The samples collected from each batch of supply of the each drugs will be sent to the empanelled testing laboratories for testing the quality of drugs. In addition to the above BPPI shall also draw the samples of products supplied in the market place and get the same tested, to make sure the products are conforming to quality requirements..

c. If such sample passes quality test in all respects, BPPI will instruct its Warehouse to release such items of drugs.

d. If the sample fails in quality test and report is received certifying that sample is “NOT OF STANDARD QUALITY”, one more sample shall be drawn from the same batch and to be sent to Government Laboratory for quality testing.

(i) If such sample passes the quality test as per the report of Government Laboratory, the drugs representing the sample shall be qualified for issue to various Institutions.

(ii) If such sample fails in the quality test, as per the report of the Government Laboratory, the drugs of the batch are not qualified for issue and the supplier shall take back the drugs supplied in that batch, besides taking other actions as per the Tender conditions by BPPI.

(iii) If such Sample fails in quality test for ASSAY content of less than 50% as per the Government Analyst report, such product of the tenderer will be blacklisted for two years.

(iv) If 3 batches of a particular item supplied by the supplier is reported to be failing in ASSAY content (above 50% but below prescribed limit) and/or other parameters, then the particular item of the firm shall be blacklisted after observing procedure laid down in Para 20.2.4 besides forfeiture of Security Deposit of that particular product(s).

f. In all the cases the reports received from the Government Drug Testing Laboratory will be conclusive and final and binding on the suppliers.

20.2.2 Quality Test by Statutory Authorities:

(a) On complaint from Drug Inspector(s) during their Test of statutory sample, that the particular drug has been reported to be of “NOT OF STANDARD QUALITY”, the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals will be retrieved. If the sample is reported to have less than 50% of content, the particular product will be **blacklisted for 2 years from the date of intimation of blacklisting.**

(b) If 4 batches of a particular item supplied by the supplier is reported to be failing in **ASSAY content (above 50% but below prescribed limit) and/or other parameters.** then the particular item of the firm shall be blacklisted for a period of **2 years** from the date of intimation after observing procedure laid down in Para 20.2.4.

(c) If a single batch of any product(s) supplied by the company/firm declared as Adulterated/spurious/ Misbranded, as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during the relevant tender period, the company/firm shall be blacklisted for a period of **5 years from the date of blacklisting** after observing procedure laid down in Para 20.2.4.

20.2.3 BLACKLISTING OF THE SUPPLIER FOR QUALITY FAILURE:

a. In case of any sample declared as Adulterated/spurious/ Misbranded, as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during, the company/firm shall be blacklisted for a period of **5 years** from the date of intimation besides forfeiture of security deposit in full after observing the procedure laid down in Para 20.2.4.

20.2.4 Procedure for Blacklisting:

(i) On receipt of report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is “**NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/ MIS-BRANDED**” (As the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, BPPI may take appropriate action on merits of the case and impose penalty including the blacklisting of the particular item of the product/company or firm as deemed fit besides forfeiture of Security deposit

(ii) If a particular item of the drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for that particular item floated by the BPPI until the period of blacklisting is over.

(iii) If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the BPPI until the period of blacklisting is over.

20.3 BLACKLISTING FOR NON-SUPPLY:

Notwithstanding various actions and penalties for non-supply and/or delayed supply of the drugs and medicines as stipulated in the terms and conditions of the tender, the BPPI shall take action against the supplier as follows:

(a) If the supplier fails to execute at least 50% of the ordered quantity as mentioned in a single Purchase order and such part supply for **any three Purchase orders of the same drug**, then the product of the supplier will be blacklisted and becomes ineligible to participate in any of the tenders for that particular item(s) by BPPI for a period of **2 years** from the date of intimation for blacklisting besides forfeiture of security deposit of that product(s)

(b) If the supplier supplies more than one item and 50% of such items are blacklisted, the firm is liable to be blacklisted for a period of **2 years from the date of intimation** besides forfeiture of security deposit in full

20.4. Purchase orders, if any, already issued before taking any blacklisting action or orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.

20.5. The blacklisting of particular product or company/firm will be done without prejudice to other penalties which may be imposed as per the conditions of Tender documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of Land. BPPI will display names of such blacklisted product(s) and company/firm on its website and also circulate the same among other state Government / Central Government and its Drug procurement agencies including respective State Drugs Control Department where the company or firm is located.

21. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

22. RESOLUTION OF DISPUTES

(i) The BPPI and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract,

ARBITRATION AND JURISDICTION

In the event of any dispute arising out of this Agreement or in connection of this Agreement between the parties hereto, the same will be referred for the arbitration to a sole arbitrator which shall be appointed with the mutual consent of the parties and the arbitration shall be at Delhi only. In case it does not reach agreement then it will be prerogative of CEO BPPI to appoint Arbitrator or Indian council of Arbitration/ICADR may nominate an Arbitrator to resolve the issue and the parties hereto agree and undertake that the decision of the sole arbitrator either appointed by mutual consent or by CEO/Indian council of Arbitration shall be final and binding on both the parties. The courts at Delhi will only have jurisdiction in connection of this Agreement.

23. APPEAL:

(i) Any Tenderer aggrieved by the order passed by the Tender Accepting Authority under section 10 of the said Act, may appeal to the Government within ten days from the date of receipt of order and the Government shall dispose the appeal within fifteen days from the date of receipt of such appeal.

(ii) No Appeal shall be preferred while the tender is in process and until tender is finalized and Notification of award is issued by the BPPI.

24. CONTACTING THE BPPI BY THE BIDDER:

(i) No bidder shall contact the *BPPI* on any matter relating to its bid, from the time of bid opening to the time the contract is awarded.

(ii) Any effort by a bidder to influence the *BPPI* in the *Purchaser's* bid evaluation, bid comparison or contract award decisions may result in rejection of the bidder's bid.

(ii) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Scrutiny Committee after opening of the bids and prior to the notification of award and any attempt by

any bidder to bring to bear extraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Scrutiny Committee, shall be sufficient reason to disqualify the bidder.

(iv) Notwithstanding anything contained in clause (iii) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

25. FRAUDULENT AND CORRUPT PRACTICES:

(1)For bidders:

It is purchaser's policy to ensure that suppliers and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. *(In this context, any action taken by a bidder, supplier, contractor, or by their authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper)* In pursuance of this policy, the purchaser;

(a) defines, for the purposes of this provision, the terms set forth below as follows:

(i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party (*"another party" refers to a public official acting in relation to the procurement process or contract execution*). In this context, "public official" includes staff and employees of other organizations taking or reviewing procurement decisions.

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (*a "party" refers to a public official; the terms "benefit" and "obligation" relate to the procurement process or contract execution; and the "act or omission" is intended to influence the procurement process or contract execution*).

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party [*"parties" refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, non competitive level*].

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (*a "party" refers to a participant in the procurement process or contract execution*).

(v) “obstructive practice” is (a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser’s inspection and audit rights provided for under sub-clause (e) below.

(b) will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question;

(c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub contractors engaged in corrupt, fraudulent, collusive, or coercive practices.

(d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

(e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

(2) For suppliers:

If the BPPI determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the BPPI may, after giving 7 days notice to the Supplier, terminate the Supplier's engagement under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 5 years with forfeiture of Security Deposit apart from other penal actions.

(a) For the purposes of this Sub-Clause:

(i) “corrupt practice” is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;

(ii) “fraudulent practice” is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;

(iii) “collusive practice” is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;

(iv) “coercive practice” is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;

(v) “obstructive practice” is (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a purchaser investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (bb) acts intended to materially impede the exercise of the purchaser’s inspection and audit rights provided for.

26. JURISDICTION

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of Delhi only.

Annexure-I
Ref. Clause No.4.1(m)

**Form Or Certificate of Sales Tax Verification To Be Produced By An Application Form
the Contract Or Other Patronage at The Disposal of The Government Of India**

(To be filled up by the applicant)

01.	Name or style in which the applicant is assessable sales tax addresses or assessment.																									
02.	a) Name and address of all companies firms or associations or persons in which the applicant is interested in his individual or fiduciary capacity.																									
	b) Places of business of the applicant (All places of business should be mentioned)																									
03.	The districts, taluks and divisions in which the applicant is assessed to sales tax (all the places of business should be furnished)																									
04	a) Total counteract amount or value of patronage received in the preceding three year:																									
	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 15%;">S. No.</th> <th style="width: 35%;">Financial Year</th> <th style="width: 50%;">Turn Over</th> </tr> <tr> <td style="text-align: center;">1.</td> <td style="text-align: center;">2011-12</td> <td></td> </tr> <tr> <td style="text-align: center;">2.</td> <td style="text-align: center;">2012-13</td> <td></td> </tr> <tr> <td style="text-align: center;">3.</td> <td style="text-align: center;">2013-14</td> <td></td> </tr> </table>		S. No.	Financial Year	Turn Over	1.	2011-12		2.	2012-13		3.	2013-14													
S. No.	Financial Year	Turn Over																								
1.	2011-12																									
2.	2012-13																									
3.	2013-14																									
	b) Particulars of Sales-Tax for the preceding three years:																									
	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 12%;">Year</th> <th style="width: 18%;">Total Turn Over be assessed</th> <th style="width: 18%;">Total Tax assessed (Rs.)</th> <th style="width: 18%;">Total Tax paid (Rs.)</th> <th style="width: 18%;">Balance due (Rs.)</th> <th style="width: 14%;">Reason for balance (Rs.)</th> </tr> <tr> <td style="text-align: center;">2011-12</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td style="text-align: center;">2012-13</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td style="text-align: center;">2013-14</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </table>		Year	Total Turn Over be assessed	Total Tax assessed (Rs.)	Total Tax paid (Rs.)	Balance due (Rs.)	Reason for balance (Rs.)	2011-12						2012-13						2013-14					
Year	Total Turn Over be assessed	Total Tax assessed (Rs.)	Total Tax paid (Rs.)	Balance due (Rs.)	Reason for balance (Rs.)																					
2011-12																										
2012-13																										
2013-14																										
	c) if there has been no assessment in any year, whether returns were submitted any, if there were, the division in which the returns were sent :																									
	d) Whether any penal action or proceeding for the recovery of Sales Tax is pending																									
	e) The name and address of Branches. If any:																									
<p>I declared that above information is correct and complete to the best of my knowledge and belief.</p> <p>Signature of Applicant: _____</p> <p>Address: _____</p> <p>Date: _____</p>																										

(To be filed by the assessing authority)

In my opinion, the applicant mentioned above has been / has not been / doing everything possible to pay the tax demand promptly and regularly and to facilitate the completion of pending proceedings.

Date seal : Deputy / Asst. Commercial tax – officer
Deputy Asst.

NOTE: Separate certificate should be obtained in respect of each of place of business of the applicant from the deputy commercial tax officer having jurisdiction over that place.

Annexure-II

Ref. Clause no 4.1 (n) (i)

DECLARATION

I do hereby declare that I will supply that I will supply the drug and medicines as per the design in enclosures to this Annexure as per the instruction given in this regard.

Signature of the Tenderer

(Name in capital letter with designation)

Attested by Notary Public

Annexure –II(A)

Ref. Clause No. 4.1 (n)(ii)

UNDERTAKING

I / we do hereby declared that I will supply the drug and medicine by the Drugs and Medicine by affixing logo on Primary/Secondary/ Tertiary for the imported items along with the generic name as per the designs given in enclosures to this annexure and as per the instruction given in this regard.

Signature of the Tenderer

(Name in capital letter with designation)

Attested by Notary Public

Enclosure – 1 to Annexure-II AND II(A) - Refer Clause No .4.1. (n)

DESIGN FOR: Foil / blister of tablet and capsule

1. Foil /Blister should be in minimum two colour i.e. Black & red
2. BPPI Logogram should be placed along with the address as given below
3. BPPI helpline number 1800 180 8080 should be printed

Manufactured for :



Bureau of Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :



Bureau of Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

4. Janaushadhi should be printed in “Inverse red colour” in English and Hindi as

Janaushadhi (In Hindi) Janaushadhi (In Hindi) Janaushadhi

Enclosure – 2 to Annexure –II & Annexure –II(A)

Ref. Clause No. 4.1.(n) & Clause No. 13

1. Design for injection for primary packing

- a) Vial (5ml or more) should be supplied with the following Jan Aushadhi logogram & BPPI as under:
- b) BPPI helpline number 1800 180 8080 should be printed



Manufactured for :



Bureau of Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :



Bureau of Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

- b) **Ampoules or Vials less than 5 ml for primary packing**
 - (i) Injection in ampoule or vial (less than 5 ml) should be supplied with BPPI logogram as under (colour should be black)

Manufactured for :



Bureau of Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :



Bureau of Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

2. LIQUID:

- a) Liquid preparation should be supplied with pilfer proof ROPP cap.
- b) Bottle cap should not bear the manufacturer's logogram
- c) Bottle label should bear JANAUSHADHI logogram as below:
- d) BPPI helpline number 1800 180 8080 should be printed



Manufactured for :



Bureau of Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

3. OINTMENTS / CREAMS

a) Ointment / Cream /Gel /Glass Jar should bear BPPI logo gram as below:

Manufactured for :



Bureau of Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

b) BPPI helpline number 1800 180 8080 should be printed

c) Ointment / cream tube should be packed in mono carton (secondary paking) with janaushadhi and BPPI logogram as given below :



Manufactured for :



Bureau of Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Enclosure 3 to Annexure – II(A)

SPECIMEN LABEL FOR MONO CARTON (Secondary Packing)

Rx
Tablets

10 X 10's

Generic Name of Product



Note: An additional to statutory requirement under Drug & Cosmetic Act 1940 and rules 1945

Manufactured for :



Bureau of Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Annexure - III

Ref. clause No. 4.1 (j)

DECLARATION

I/We M/s. Represented by its Proprietor/Managing Partner
/Managing Director having its registered office atand its
factory premises atand
its factory premises at

.....do declare that I/we have carefully read all the conditions of tender in ref.
no. **BPPI/DRUG/016 Dt. 28/01/2015** public sector under taking of INDIA, GURGAON,
122016 and all accepts all conditions of the Tender.

I/We declare that we possess the valid drug manufacturing licence and GMP
Certificate as per schedule M issued by competent authority and complies and continue to
comply with the condition lied in schedule M of Drug & cosmetic act, 1940 the rules made
there under. I /we furnish the particulars in this regard in enclosure to this declaration.

I am / We are aware of the Tender inviting Authority's right to forfeit the Earnest
Money Deposit and /or Security Deposit and blacklist me/us for a period of 5 year if, any
information furnished by us proved to be false at time the of inspection and not complying
the condition as per schedule M of the said Act for a period of five years.

Signature :

Name & Address:

Seal:

To be Notarized.

Enclosure to Annexure – III Clause 4.1(j)

DECLARATION FOR COMPLIANCE OF G.M.P.

S.No.	Description	To be filled Tenderer																		
1.	Name & Address of the firm																			
2.	Name of proprietor / partner /Director																			
3.	Name and Designation of qualified personal <table border="1" style="margin-top: 10px;"> <tr> <td>a)</td><td>Manufacturing</td><td>Name: Designation:</td></tr> <tr> <td>b)</td><td>Testing</td><td>Name: Designation:</td></tr> </table>	a)	Manufacturing	Name: Designation:	b)	Testing	Name: Designation:													
a)	Manufacturing	Name: Designation:																		
b)	Testing	Name: Designation:																		
4.	G.M.P. Certificate as per Revised schedule “M”																			
5.	Details of licenses held with validity																			
6.	Number of workers Employed <table border="1" style="margin-top: 10px;"> <tr> <td>Gents</td><td></td></tr> <tr> <td>Ladies</td><td></td></tr> </table>	Gents		Ladies																
Gents																				
Ladies																				
7.	Whether workers provided with Uniform	YES/NO																		
8.	Whether medical Examination done for workers	YES/NO																		
9.	Hygienic Condition <table border="1" style="margin-top: 10px;"> <tr> <td>a)</td><td>Surrounding</td><td>Satisfactory / Not satisfactory</td></tr> <tr> <td>b)</td><td>Production Areas</td><td>Satisfactory / Not satisfactory</td></tr> <tr> <td>c)</td><td>Other Area</td><td>Satisfactory / Not satisfactory</td></tr> </table>	a)	Surrounding	Satisfactory / Not satisfactory	b)	Production Areas	Satisfactory / Not satisfactory	c)	Other Area	Satisfactory / Not satisfactory										
a)	Surrounding	Satisfactory / Not satisfactory																		
b)	Production Areas	Satisfactory / Not satisfactory																		
c)	Other Area	Satisfactory / Not satisfactory																		
10.	Provision for disposal of waste	YES/NO																		
11.	Heating, Ventilation, Air conditional system & AHU	YES/NO																		
12.	Weather work Benches provided in all Working Area	YES/NO																		
13.	Water Supply <table border="1" style="margin-top: 10px;"> <tr> <td>a)</td><td>Source <table border="1" style="margin-top: 5px;"> <tr> <td>DM Plant</td><td></td></tr> <tr> <td>Purified Water/R.O.</td><td></td></tr> <tr> <td>Water for Injection Plant</td><td></td></tr> </table> </td><td></td></tr> <tr> <td>b)</td><td>Storage Condition</td><td>Satisfactory / Not satisfactory</td></tr> <tr> <td>c)</td><td>Testing (With Reference to Pathogenic Organization)</td><td>YES/NO</td></tr> <tr> <td>d)</td><td>Cleaning Schedule in Water Supply System with Proper</td><td>YES/NO</td></tr> </table>	a)	Source <table border="1" style="margin-top: 5px;"> <tr> <td>DM Plant</td><td></td></tr> <tr> <td>Purified Water/R.O.</td><td></td></tr> <tr> <td>Water for Injection Plant</td><td></td></tr> </table>	DM Plant		Purified Water/R.O.		Water for Injection Plant			b)	Storage Condition	Satisfactory / Not satisfactory	c)	Testing (With Reference to Pathogenic Organization)	YES/NO	d)	Cleaning Schedule in Water Supply System with Proper	YES/NO	
a)	Source <table border="1" style="margin-top: 5px;"> <tr> <td>DM Plant</td><td></td></tr> <tr> <td>Purified Water/R.O.</td><td></td></tr> <tr> <td>Water for Injection Plant</td><td></td></tr> </table>	DM Plant		Purified Water/R.O.		Water for Injection Plant														
DM Plant																				
Purified Water/R.O.																				
Water for Injection Plant																				
b)	Storage Condition	Satisfactory / Not satisfactory																		
c)	Testing (With Reference to Pathogenic Organization)	YES/NO																		
d)	Cleaning Schedule in Water Supply System with Proper	YES/NO																		

		Records	
	e)	Type of Machinery installed as to Semi Automatic or Fully Automatic plant for Water purification system along with cost and whether this is working, and if so the flow rate of Pharmaceutical water to must the requires preparation	
14.	Air handling system along with the list of machine and cost of the unit. Separately for sterile and non sterile preparation		
	S.No.	Utilities	
	a)	Compressed air/nitrogen	
	b)	Vacuum	
	c)	Steam(boiler)	
15.	Whether the pollution control clearance is valid for Air and water and if so the period upto which valid (copy of the certificate to be enclosed)		
16.	Raw Material Storage Area (Storage Facilities / Hygienic Condition)		
	a)	Quarantine	Provided/Not Provided
	b)	Passed Materials	Provided/Not Provided
	c)	Rejected Materials	Provided/Not Provided
17.	Finished Product Storage Area (Hygienic / Storage)		
	a)	Quarantine	Provided/Not Provided
	b)	Released Materials	Provided/Not Provided
18.	Details of Technical Staff		
		Name	Qualification
	For Manufacturing		
	For Testing		
19.	Testing Facilities (List of Equipments to be furnished separately in the format to meet the bench mark vide Annexure)		
	a)	Chemical Method	YES/NO
	b)	Instrumental (Type of Instrument Provided as indicated in Annexure)	YES/NO
	c)	Biological	YES/NO
	d)	Micro Biological	YES/NO
	e)	Animal Testing	YES/NO
20.	Remarks		
	a)	Whether Products Quoted to BPPI are Endorsed in the Licence	YES/NO
	b)	Whether the drugs Quoted to BPPI have been Manufactured Earlier(Last 03 Years)	YES/NO
	If Yes, Details Like		

S.No.	Date of Manufacturer	Name of the Drug	Batch No.	Batch Size	Date of Release

c) Production Capacity (Section Wise)

Tablet Section :

Type of Equipments	No. of Equipments	Production Capacity of all the Equipments in Column 2 per shift	No of Shift	Production Capacity allotted for BPPI
(1)	(2)	(3)	(4)	(5)
Planetary Mixer				
Fluidized Bed Drier				
Tray Drier				
Mechanical Shifter				
Multi Mill				
Tablet Compression Machine				
1. With _____ number of station				
2. With _____ number of station				
3. With _____ number of station				
4. With _____ number of station				
Coating Pan				
Blister Packing Machine				
Strip Packing Machine				

Capsule Section:

Type of Equipments	No. of Equipments	Production Capacity of all the	No of Shift	Production Capacity allotted for
--------------------	-------------------	--------------------------------	-------------	----------------------------------

(1)	(2)	Equipments in Column 2 per shift (3)	(4)	BPPI (5)
Double Cone Blender				
Automatic capsule filling machine				
Semi Automatic Capsule filling machine				
Hand filling machine				
Blister packing machine				
Strip packing machine				

Parenteral Section:

Type of Equipments (1)	No. of Equipments (2)	Production Capacity of all the Equipments in Column 2 per shift (3)	No of Shift (4)	Production Capacity allotted for BPPI (5)
Small volume Parenteral				
Mixing Vessel				
Laminar Flow Unit				
Filtration Unit				
Ampoule filling Machine(with No of head)				
Vial Filling Machine(with No of head)				
Vial sealing machine				
Powder filling machine				
Autoclave for terminal Sterilization				

Ampoule labelling machine				
Vials labelling machine				

Large Volume Parenterals:

Type of Equipments (1)	No. of Equipments (2)	Production Capacity of all the Equipments in Column 2 per shift (3)	No of Shift (4)	Production Capacity allotted for BPPI (5)
Mixing Vessel				
Filtration Unit				
Filling Machine Autoclave for terminal Sterilization				
Labelling Machine				

Ointment/Cream

Type of Equipments (1)	No. of Equipments (2)	Production Capacity of all the Equipments in Column 2 per shift (3)	No of Shift (4)	Production Capacity allotted for BPPI (5)
Stream jacket vessel for mixing				
Ointment/cream filling machine				

Liquid Section:

Type of Equipments	No. of Equipments	Production Capacity of all the Equipments in Column 2 per shift	No of Shift	Production Capacity allotted for BPPI

	(1)	(2)	(3)	(4)	(5)
	Bottle washing machine				
	SS tank with capacity				
	Filter press				
	Colloidal mill				
	Bottle Filling Machine				
	Labelling Machine				
External Preparation:					
	Type of Equipments	No. of Equipments	Production Capacity of all the Equipments in Column 2 per shift	No of Shift	Production Capacity allotted for BPPI
	(1)	(2)	(3)	(4)	(5)
	Mixing Vessel				
	Filling Machine				
	Labelling Machine				
d)	Any, Not of Standard Quality Reports of Product Quoted/Approved by BPPI (If Not, Nil Statement)			YES/NO	
e)	Any Prosecution after submission of tender Documents (If Not, Nil Statement)			YES/NO	
f)	Chances of Cross Contamination at Raw Materials/In Process/Finished Product Stage and Steps/Facilities			YES/NO	
g)	Validation of Equipment done			YES/NO	
h)	Cleaning Schedule :				
	1.	For Premises			
	2.	For Equipments			
i)	Adverse Reaction, if any and Reported:				
	S.No.	Description	Remarks		
	1.	Whether any drug(s) manufactured by the tenderer has/have been recalled during last five years? If yes given details			
	2.	What are the results of investigations on the recalled drug(s)?			

		3.	What action have been taken to prevent recurrence of recall of drug(s) on that particular account?	
	j)	Complaints Received If Any and Steps taken:		
		S.No.	Description	Remarks
		1.	Whether any drug(s) manufactured by the tenderer has/have been recalled during last five years? If yes given details	
		2.	What are the results of investigations on the recalled drug(s)?	
		3.	What action have been taken to prevent recurrence of recall of drug(s) on that particular account?	
Signature and Seal of Proprietor/Partner/Director				
To be attested by the Notary:				

Annexure

S.No, (1)	Name of the Instruments (2)	No. of Instruments (3)	Cost of Instruments (4)	Whether it is in working Condition (5)
1.	Analytical Balance			
2.	Infra Red Spectrometer			
3.	Karl Fisher Tritator			
4.	Melting Point			
5.	Brookfield Viscometer			
6.	Polarimeter			
7.	Autoclave			
8.	Refractometer			
9.	Sampling Booth			
10.	UV-Vis Spectrometer			
11.	HPLC			
12.	Muffle Furnace			
13.	Fuming Cupboard			
14.	Micrometer			
15.	Dissolution Tester			
16.	Disintegration Tester			
17.	Friability Tester			
18.	Vernier Callipers'			
19.	IR Balance			
20.	Hardness Tester			
21.	Leak test Apparatus			
22.	Laminar Air Flow			
23.	BOD Incubator			
24.	Vacuum Oven			
25.	Bulk Density Apparatus			
26.	Water Activity Meter			
27.	Anaerobic System			
28.	Gas Chromatograph			
29.	LAL Kit			
30.	Sterility Test Kit			
31.	Particle Counter			
32.	Air Sampler			
33.	Flame Photometer			
34.	Tap Density Tester			

Annexure-IV

Ref. Clause No. 2(e)(i)

DECLARATION

I
Managing Director/Partner/Proprietor of M/s.
.....
having its manufacturing or import unit/ registered office at.....do
hereby declare that our company/applied items have not been blacklisted either by any State
government or Central Government Organization or its drug procurement agencies for the
following products quoted in the tender during last three years. We are eligible to participate
in the tender ref. No. **BPPI/DRUG/016 Dt. 28-01-2015** for the following products.

S. No.	Drug Code	Name of the Drug

M/s.....

(Company Seal)

To be attested by the Notary

Annexure-V

Ref. Clause No. 7.1 & 3(iv)

DETAILS OF E.M.D SUBMITTED

We herewith submit the E.M.D. of Rs.....in the form of Demand
Draft bearing No..... Dated:drawn
on.....BankBranch in favour of
Bureau of Pharma Public sector Undertakings of India.

Signature & Seal

Annexure-VI

Ref. Clause No. 7.2

NOTORISED UNDERTAKING

(In 20-Rupees Stamp Paper)

I.....,S/o.....,Proprietor/Partner/
Managing Director of(Proprietary Concern/Firm/Company Ltd.)
execute this undertaking for myself and on behalf
of.....(Proprietary Concern/Firm/Company Ltd.).

And whereas, in pursuant to the conditions in Clause No. 7.2 of the tender, the Earnest Money Deposit can be forfeited by the Tender Inviting Authority in case of violation of any of the conditions and non-performance of the obligation under tender document.

M/s.....

For Self and Firm/Company Ltd.

(Signature and Seal)

Witness:-

(1).....

(2).....

Annexure-VII

Ref. Clause No. 4.1(h)

PROFORMA FOR PERFORMANCE STATEMENT

(For a Period of Last 5 Years)

Certified that M/sholding drug license no
..... .. has manufactured & sold the following products for last 3 years as
per details below:

S.No.	Name of the Product	Year of Manufacturing	No. of batches manufactured/imported & supplied	Batch No. Batch Size	Name and full address of the purchaser
1.					
2.					
3.					
4.					
5.					

State Licensing Authority

Signature and seal of the Tenderer.....

Annexure-VIII

Ref. Clause No. 4.1(k)

ANNUAL TURNOVER STATEMENT

The annual Turnover of M/s.for the past three years are given below and certified that the statement is true and correct.

Sl.No.	Financial Year	Turnover in Lakhs(Rs.)
1.	2011-12	
2.	2012-13	
3.	2013-14	
TOTAL		Rs.....Lakhs
Average Turnover per annual		Rs.....Lakhs

Date:

Signature of Auditor/Chartered Account

Seal:

(Name in Capital)

Annexure- IX
Ref Clause 8.1 & 8.2

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
1	5	ASPIRIN TABLETS IP 150 MG	14's	14'sx10	466,000	14'sx10x10
2	6	DICLOFENAC 50 MG+ PARACETAMOL 325 MG+ CHLORZOXAZONE 500 MG TABLETS	10's	10'sx10	75,000	10'sx10x10
3	40	AMOXICILLIN 250 MG+ CLOXACILLIN 250 MG CAPSULES	9's	9'sX10	52,000	9'Sx10x10
4	60	CEFOTAXIME SODIUM 250 MG & SULBACTAM SODIUM 125 MG INJECTION	1Vial & wfi	1Vial & wfix100	75,000	10'sx20
5	83	CIPROFLOXACIN 250 MG+ TINIDAZOLE 300 MG TABLETS	10's	10'sx10	96,000	10'sx10x10
6	89	CO-TRIMOXAZOLE TABLETS IP (160 MG + 800 MG)	10's	10'sx10	120,000	10'sx10x10
7	98	NORFLOXACIN 400 MG + TINIDAZOLE 600 MG FILM COATED TABLETS	10's	10'sx10	20,000	10'sx10x10
8	109	VANCOMYCIN INJECTION IP 500 mg	VIAL & WFI	5 VIALS	2,00,000	4x 5x 10
9	112	BECLOMETHASONE IP 0.025% w/w+ CLOTRIMAZOLE IP 1% w/w+ GENTAMYCIN IP 0.1% w/w CREAM	15 GM	15 GMX20	2,70,000	15 gm x 20x 10
10	117	CHLORHEXIDINE MOUTHWASH IP 2 % w/v	160 ML	160 ML	111,000	160 MLX50
11	142	INSULIN INJECTION IP 40 IU/ML (Insulin Human Recombinant)	10 ML VIAL	10 MLX10	136,000	10 MLX10X20
12	143	BIPHASIC INSULIN ASPART INJECTION IP 100 IU/ML (30:70)	VIAL	VIALX10	47,000	VIALX10X100
13	144	METFORMIN HYDROCHLORIDE TABLETS IP SR 1000 MG	10's	10'sx10	9,000	10'sx10x10
14	153	CISPLATIN INJECTION IP 10 MG	VIAL	1X20	100,000	1 X 20 X 50
15	165	CIPROFLOXACIN INJECTION IP 2MG/ML	100 ML	100 ML x 6	36,000	100 ML x 6 x20
16	170	MANNITOL INJECTION IP 20% w/v	100 ML	100 ML x 6	100,000	100 ML x 6 x20
17	172	METRONIDAZOLE INJECTION IP 5 MG /ML	100 ML	100 ML x 6	120,000	100 ML x 6 x20
18	178	ALBENDAZOLE 400 MG + IVERMECTIN 6 MG TABLETS	1's	1'sx10	177,000	1X10X100
19	181	TRICHOLINE CITRATE 275 MG+ CYPROHEPTADINE HCl 2 MG/5ml SYRUP	200 ML	200 ML	202,000	200MLX40

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA,
GURGAON-122016**

**TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016
DT 28-01-2015**

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
20	188	ANTACID TABLETS [DRIED Al(OH) ₃ + Mg(OH) ₂ + SIMETHICONE (250MG + 250MG + 50MG)	10's	10'sx10	4,000	10'sx10x10
21	191	FAMOTIDINE TABLETS IP 20 MG	10's	10'sx10	485,000	10'sx10x10
22	192	FAMOTIDINE TABLETS IP 40 MG	14's	14'sx10	1,010,000	14'sx10x10
23	196	LACTOBACILLUS SPOROGENES 60 MILLION SPORES TABLETS	10's	10'sx10	243,000	10'sx10x10
24	208	ONDENSETRON INJECTION IP 2 mg/ml	2 ML	2 ml x 10	1,20,000	2 ml x 10 x 50
25	216	RANITIDINE INJECTION IP 50 MG/ 2ML	2 ML	2 ml x 10	760,000	2 MLX10X10
26	218	RANITIDINE TABLETS IP 300 MG FILM COATED	10's	10'sx10	1,723,000	10'sx10x10
27	223	PYRIDOXINE HCl 10 MG+ DOXYLAMINE 10 MG + FOLIC ACID 2.5 MG TABLETS	30's	30'Sx10	100,000	30'Sx10x10
28	225	IRON HYDROXIDE POLYMALTOSE COMPLEX EQ TO ELEMENTAL IRON 50 MG+ FOLIC ACID 0.5 MG /15 ML SYRUP	200 ML	200 ML	1,00,000	200MLX40
29	230	VITAMIN B COMPLEX WITH ZINC CAPSULES	20's	20'sX10	517,000	20'sX10X10
30	231	VITAMIN B1 10MG, B2 10 MG, NIACINAMIDE 45 MG, CALCIUM PANTOTHENATE 50 MG, B6 3 MG AND B12 15 MCG TABLETS	10's	10'sx10	1,924,000	10'sx10x10
31	232	VITAMIN B-VOMPLEX NFI Syrup	200 ML	200 ML	2,00,000	200MLX40
32	235	BUDESONIDE RESPULES 0.5 MG	2 ML	2 ml x 10	912,000	2 ml x 10 x 100
33	241	COUGH SYRUP [DEXTROMETHORPHAN HBR 10 mg+ CPM 10 MG /10 ML SYRUP	100 ml	100 ML X6	1,85,000	100 MLX6X20
34	242	COUGH SYRUP [CPM 3 MG. + ALU.CHL.110 MG. +SOD. CIT.46 MG. + MENTHOL 0.9 MG /5 ML]	110 ML	110 MLX6	120,000	110 MLX10X10
35	243	COUGH SYRUP [DIPHEN.14 MG. + ALU.CHL.135 MG. + SOD.CIT.57 MG. + MENTHOL 0.9 MG/5ML]	110 ML	110 MLX6	120,000	110 MLX10X10
36	244	THEOPHYLLINE 25.3 MG+ ETOPHYLLINE 84.6MG INJECTION 2 ML	2 ML	2 ml x 10	1,746,000	2 ml x 10 x 100
37	253	PHENIRAMINE TABLETS IP 25 MG	15's	15'sx10	1,298,000	15'sx10x10
38	255	SALBUTAMOL INHALATION IP 100 µg	200 MD	200 MD	182,000	200 MD X100
39	270	ASPIRIN 75 MG + CLOPIDOGREL 75 MG TABLETS	10's	10'sx10	439,000	10'sx10x10

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
40	278	FRUSEMIDE INJECTION IP (10 MG/ ML)	2 ML	2 ml x 10	107,000	2 MLX10X10
41	285	AMLODIPINE 5 MG + LISINOPRIL 5 MG TABLETS	15's	15'sx10	103,000	15'sx10x10
42	299	TELMISARTAN TABLETS IP 20 mg	10's	10'sx10	2,00,000	10'sx10x10
43	302	TRANEXAMIC ACID 500 MG/5 ML	5 ML AMPULE	5 ML X 10	2,10,000	5 MLX10X50
44	306	PRIMAQUINE TABLETS IP 15 MG	7's	7's X 10	120,000	7'sx10x10
45	323	FLUNARZINE TABLETS 10MG	10's	10'sx10	200,000	10'sx10x10
46	324	FLUNARZINE TABLETS 5MG	10's	10'sx10	95,000	10'sx10x10
47	327	PHENYTOIN TABLETS IP 100 MG	100's in Bottle	100 ML X6	125,000	100 MLX6X20
48	329	PREDNISOLONE TABLETS IP 5 MG	15's	15'sx10	1,573,000	15'sx10x10
49	331	THYROXINE SODIUM TABLETS IP 50 µg	10's	10'sx10	210,000	10'sx10x10
50	334	DEXAMETHASONE INJECTION IP 4 MG/ML	2 ML	2 ml x 10	1,112,000	2 ml x 10 x 100
51	338	ATROPINE SULPHATE INJECTION IP 0.6MG/ ML	1 ML	1 MLX10	100,000	1 ML X10X100
52	341	CARBOXY METHYL CELLULOSE EYE DROPS IP 0.5% w/v	10 ML	10 MLX10	100,000	10 MLX10X20
53	356	LIGNOCAINE INJECTION IP 2% w/v	20 ML VIAL	20 ML X 10	2,00,000	20 ml x 10 x 10
54	359	TETANUS VACCINE (Adsorbed) IP	AMP 0.5 ML	1X10	1,160,000	1x10 x100
55	360	MIFEPRISTONE TABLETS 200 MG	1's	1'sx10	60,000	1X10X100
56	361	OXYTOCIN INJECTION 5 iu/ ml	1 ML	1 ML X 10	10,00,000	1 MLX10X100
57	362	BIPHASIC ISOPHANE INSULIN INJECTION IP 40 IU/ML (50:50)	10 ML VIAL	10 MLX10	340,000	10 MLX10X20
58	363	GLARGINE 100 IU INJECTION	CARTRIDGE 3 ML	3 ML X 10	72,000	3 ML X 10 X 100
59	364	GLIMEPIRIDE 2 MG + METFORMIN HYDROCHLORIDE 500 MG TABLETS SR	15's	15'sx10	795,000	15'sx10x10

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
60	365	GLICLAZIDE 80 MG + METFORMIN HYDROCHLORIDE TABLETS 500 MG	15's	15'sx10	666,000	15'sx10x10
61	366	GLIPIZIDE 5 MG + METFORMIN HYDROCHLORIDE 500 MG TABLETS	10's	10'sx10	1,309,000	10'sx10x10
62	367	VOGLIBOSE TABLETS IP 0.3 MG	10's	10'sx10	380,000	10'sx10x10
63	368	GLICLAZIDE TABLETS SR 60 MG	14's	14'sx10	55,000	14'sx10x10
64	369	ACARBOSE TABLETS IP 50 MG	10's	10'sx10	46,000	10'sx10x10
65	370	NEUTRAL PROTAMINATED HAGEDORN INJECTION 40 IU	10 ML VIAL	10 MLX10	40,000	10 MLX10X20
66	371	VOGLIBOSE TABLETS IP 0.2 MG	10's	10'sx10	243,000	10'sx10x10
67	372	METFORMIN HYDROCHLORIDE TABLETS IP SR 500 MG	10's	10'sx10	9,000	10'sx10x10
68	373	ARTESUNATE INJECTION 60 MG	1 ML	1 MLX10	99,000	1 MLX10X100
69	374	ARTEMETHER 80 MG + LUMEFANTRINE 480 MG TABLETS	6's	6's X 10	91,000	6's X 10 X 10
70	375	QUININE SULPHATE TABLETS IP 300 MG FILM COATED TABLETS	10's	10'sx10	44,000	10'sx10x10
71	376	IMIPENEM AND CILASTATIN INJ IP (500MG+500MG)	20 ML	20MLX10	36,000	20MLX10X10
72	377	CLINDAMYCIN CAPSULES IP 300 MG	10's	10'sx10	22,000	10'sx10x10
73	378	RIFAMPICIN, ISONIAZIDE, ETHAMBUTOL and PYRAZINAMIDE TABLETS IP (450MG+300MG+800MG+750MG) KIT	1's	1'sx10	655,000	1X10X100
74	379	RIFAMPICIN and ISONIAZIDE TABLETS IP (450 MG+300 MG)	10's	10'sx10	144,000	10'sx10x10
75	380	CLARITHROMYCIN TABLETS IP 500 MG	4's	4'sx10	42,000	4'sx10x10
76	381	CEFIXIME 200 MG + OFLOXACIN 200 MG TABLETS	10's	10'sx10	537,000	10'sx10x10
77	382	LINEZOLID TABLETS IP 600 MG	10's	10'sx10	95,000	10'sx10x10
78	383	CEFPODOXIME 200 MG+ CLAVULANIC ACID 125 MG TABLETS	6's	6'sx10	286,000	6's X 10 X 10
79	384	ITRACONAZOLE CAPSULES 100 MG	4's	4'sx10	139,000	4'Sx10x10

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
80	385	CEFIXIME 200 MG + CLAVULANIC ACID 125 MG TABLETS	10's	10'sx10	170,000	10'sx10x10
81	386	DIETHYLCARBAMAZINE TABLETS IP 50 MG	30's	30'sx10	172,000	30'sx10x10
82	387	TERBINAFINE 250 MG TABLETS	7's	7'sx10	206,000	7'sx10x10
83	388	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG and ETHAMBUTOL TABLET IP 800MG	1's	1'sx10	484,000	1X10X100
84	389	PENICILLIN G 400000 IU TABLETS	6's	6'sX10	684,000	6's X 10 X 10
85	390	ETHAMBUTOL TABLETS IP 800 MG	10's	10'sx10	129,000	10'sx10x10
86	391	MOXIFLOXACIN TABLETS 400 MG	5's	5'sx10	134,000	5'sx10x100
87	392	GRISEOFULVIN TABLETS IP 250 MG	10's	10'sx10	220,000	10'sx10x10
88	393	ACICLOVIR TABLETS IP 800 MG	5's	5'sx10	47,000	5'sx10x100
89	394	PYRANTEL PAMOATE ORAL SUSPENSION IP 250 MG/10 ML	10 ML	10 MLX10	237,000	10 MLX10X20
90	395	CEFUROXIME 500 MG+ CLAVULANIC ACID 125 MG TABLETS	6's	6'sX10	68,000	6'sX10X10
91	396	AMPHOTERICIN B INJECTION 50 MG	20 ML	20MLX10	4,000	20MLX10X10
92	397	OXYTETRACYCLINE CAPSULES IP 250 MG	8's	8'Sx10	486,000	8'Sx10x10
93	398	RIFAMPICIN TABLETS IP 450 MG	10's	10'sx10	28,000	10'sx10x10
94	399	RIFAMPICIN, ISONIAZIDE and PYRAZINAMIDE TABLETS IP (100MG+50MG+300MG)	10's	10'sx10	76,000	10'sx10x10
95	400	KETOCONAZOLE TABLETS IP 200 MG	10's	10'sx10	12,000	10'sx10x10
96	401	AMOXYCILLIN and POTASSIUM CLAVULANATE TABLETS IP (250MG+150MG)	6's	6'sX10	432,000	6'sX10X10
97	402	AMOXYCILLIN and POTASSIUM CLAVULANATE TABLETS IP (875MG+125MG)	6's	6'sX10	1,488,000	6'sX10X10
98	403	CLINDAMYCIN INJ IP 300 MG/2 ML	2 ML	2 ml x 10	38,000	2 ml x 10 x 100
99	404	LINEZOLID INFUSION 300 MG/200 ML	200 ML	200 ML	577,000	200MLX40

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
100	405	OFLOXACIN INFUSION IP 200 MG /100 ML	100 ML	100 ML X6	80,000	100 MLX6X20
101	406	ACICLOVIR INTRAVENOUS INFUSION IP 500 MG/VIAL	VIAL	10'S	98,000	10'SX20
102	407	IVERMECTIN TABLETS 12 MG	10's	10'sx10	120,000	10'sx10x10
103	408	BENZYPENICILLIN INJECTION IP 0.6 MILLION UNITS	VIAL	10'S	120,000	10'SX20
104	409	BENZYPENICILLIN INJECTION IP 1.2 MILLION UNITS	VIAL	10'S	120,000	10'SX20
105	410	TRASTUZUMAB INJECTION 400 MG	1's	1'sX10	1,000	1X10X10
106	411	BEVACIZUMAB INJECTION 100 MG	1's	1'sX10	1,000	1X10X10
107	412	AZATHIOPRINE TABLETS IP 50 MG	10's	10'sx10	57,000	10'sx10x10
108	413	METHOTREXATE TABLETS IP 7.5 MG	10's	10'sx10	35,000	10'sx10x10
109	414	TRANEXAMIC ACID 500 MG+ MEFENAMIC ACID 250 MG TABELTS	10's	10'sx10	125,000	10'sx10x10
110	415	GLYCERYL TRINITRATE TABLETS IP 250 µg	25's	25'sx10	194,000	25'sx10x20
111	416	PRAZOSIN TABLETS IP 5 MG	15's	15'sx10	137,000	15'sx10x10
112	417	TELMISARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	15's	15'sx10	675,000	15'sx10x10
113	418	ROSUVASTATIN TABLETS IP 20 MG	10's	10'sx10	166,000	10'sx10x10
114	419	HEPARIN SODIUM 50 IU/20 GM OINTMENT	20 GM	20 GMx20	139,000	20 GMx20X10
115	420	ATORVASTATIN 10 MG+ CLOPIDOGREL 75 MG TABLETS	10's	10'sx10	63,000	10'sx10x10
116	421	NEBIVOLOL HYDROCHLORIDE TABLETS IP 5 MG	10's	10'sx10	234,000	10'sx10x10
117	422	TORSEMIDE TABLETS 10 MG	15's	15'sx10	210,000	15'sx10x10
118	423	BISOPROLOL TABLETS 5 MG	10's	10'sx10	121,000	10'sx10x10
119	424	CARVEDILOL TABLETS IP 3.125 MG	10's	10'sx10	258,000	10'sx10x10

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
120	425	DILTIAZEM TABLETS IP SR 90 MG	10's	10'sx10	65,000	10'sx10x10
121	426	ACENOCOUMAROL TABLETS IP 2 MG	30's	30'Sx10	26,000	30'Sx10x10
122	427	S-AMLODIPINE TABLETS IP 2.5 MG	10's	10'sx10	366,000	10'sx10x10
123	428	DIGOXIN TABLETS IP 250 µg	10's	10'sx10	374,000	10'sx10x10
124	429	ATORVASTATIN 10 MG+ FENOFIBRATES 160 MG TABLETS	15's	15'sx10	190,000	15'sx10x10
125	430	AMIODARONE TABLETS IP 200 MG	10's	10'sx10	43,000	10'sx10x10
126	431	RAMIPRIL and HYDROCLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	10's	10'sx10	60,000	10'sx10x10
127	432	OLMESARTAN TABLETS 40 MG	10's	10'sx10	185,000	10'sx10x10
128	433	ISOSORBIDE-5-MONONITRATE TABLETS IP 30 MG	30's	30'Sx10	42,000	30'Sx10x10
129	434	PROPRANOLOL TABLETS IP 40 MG	10's	10'sx10	115,000	10'sx10x10
130	435	ROSUVASTATIN 10 MG + FENOFIBRATES 160 MG TABLETS	10's	10'sx10	99,000	10'sx10x10
131	436	TELMISARTAN 40 MG+ CHLORTHALIDONE 12.5 MG TABLETS	10's	10'sx10	124,000	10'sx10x10
132	437	NIFEDIPINE SUSTAINED RELEASE TABLETS IP 20 MG	10's	10'sx10	324,000	10'sx10x10
133	438	INDAPAMIDE TABLETS IP 1.5 MG	10's	10'sx10	50,000	10'sx10x10
134	439	OLMESARTAN 40 MG + HYDROCLORTHIAZIDE 12.5 MG TABLETS	10's	10'sx10	146,000	10'sx10x10
135	440	METOPROLOL 50 MG + AMLODIPINE 5 MG TABLETS	7's	7'sx10	400,000	7'sx10x10
136	441	LOSARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	10's	10'sx10	278,000	10'sx10x10
137	442	FENOFIBRATE CAPSULES IP 150 MG	10's	10'sx10	42,000	10'sx10x10
138	443	ISOSORBIDE DINITRATE TABLETS IP 5 MG	50's	50'sx10	122,000	50'sx10X50
139	444	ENALAPRIL 10 MG + HYDROCLORTHIAZIDE 25 MG TABLETS	30's	30'Sx10	24,000	30'Sx10x10

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA,
GURGAON-122016**

**TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016
DT 28-01-2015**

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
140	445	OLMESARTAN 5 MG+ AMLODIPINE 20 MG TABLETS	10's	10'sx10	112,000	10'sx10x10
141	446	AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE 12.5 MG TABLETS	10's	10'sx10	173,000	10'sx10x10
142	447	MOXONIDINE TABLETS 0.3 MG	10's	10'sx10	55,000	10'sx10x10
143	448	AMLODIPINE 5 MG+ RAMIPRIL 5 MG TABLETS	10's	10'sx10	15,000	10'sx10x10
144	449	SPIRONOLACTONE TABLETS IP 25 MG	15's	15'sx10	67,000	15'sx10x10
145	450	LABETALOL TABLETS IP 100 MG	10's	10'sx10	25,000	10'sx10x10
146	451	STREPTOKINASE INJECTION IP 1500000 IU	10 ML	10 MLX10	2,000	10 MLX10X20
147	452	WARFARIN TABLETS IP 5 MG	10's	10'sx10	76,000	10'sx10x10
148	453	BISOPROLOL 5 MG+ HYDROCHLOROTHIAZIDE 6.25 MG TABLETS	10's	10'sx10	22,000	10'sx10x10
149	454	VALSARTAN TABLETS IP 80 MG	10's	10'sx10	14,000	10'sx10x10
150	455	VERAPAMIL TABLETS IP 80 MG	10's	10'sx10	120,000	10'sx10x10
151	456	ATORVASTATIN TABLETS IP 40 MG	10's	10'sx10	432,000	10'sx10x10
152	457	TORSEMIDE TABLETS 20 MG	10's	10'sx10	210,000	10'sx10x10
153	458	LABETALOL INJECTION IP 5 MG/ML	4 ML VIAL	4 MLX100	25,000	4 MLX10X20
154	459	HYDROQUINONE 2 MG + MOMETASONE 0.1 MG+ TRETINOIN 0.025 % CREAM	20 GM	20 GMx20	402,000	20 GMx20X10
155	460	TERBINAFINE 1 MG + CLOBETASOL 0.05 MG + OFLOXACIN 0.75 MG + ORNIDAZOLE 2 % w/w CREAM	15 GM	15 GMx20	604,000	15 GMx20x10
156	461	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM	20 GMx20	1,513,000	20 GMx20X10
157	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12w/w+3%w/w)	30 GM	30 GMX10	701,000	30 GMX10X10
158	463	MUPIROCIN OINTMENT IP 2 % w/w	5 GM	5 GM X20	352,000	5 GM X20X50
159	464	DICYCLOMINE 10 MG + PARACETAMOL 325 MG + TRAMADOL 50 MG CAPSULES	8's	8'sX10	1,287,000	8'sX10X10

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
160	465	DOMPERIDONE 30 MG+ PANTOPRAZOLE 40 MG CAPSULES	10's	10'sx10	895,000	10'sx10x10
161	466	URSODEOXYCHOLIC ACID TABLETS IP 300 MG	10's	10'sx10	236,000	10'sx10x10
162	467	DICYCLOMINE 10 MG+ MEFENAMIC ACID 250 MG TABLETS	10's	10'sx10	740,000	10'sx10x10
163	468	ENTEROGERMINA ORAL SUSPENSION 200 MILLION/ 5 ML	100 ML	100 ML X6	425,000	100 MLX6X20
164	469	HEPATIC PROTECTORS SYRUP	200 ML	200 ML	640,000	200MLX40
165	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ML	200 ML	234,000	200MLX40
166	471	OXETACAINE 10 MG+ ALUMINIUM 291 MG + MAGNESIUM 98 MG /5 ML GEL	200 ML	200 ML	211,000	200MLX40
167	472	DOMPERIDONE 30 MG+ ESOMEPRAZOLE 40 MG CAPSULE	10's	10'sx10	133,000	10'sx10x10
168	473	LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40 MG CAPSULE	10's	10'sx10	56,000	10'sx10x10
169	474	DOXYLAMINE 10 MG+ PYRIDOXINE HCl 10 MG TABLETS	30's	30'Sx10	142,000	30'Sx10x10
170	475	SUCRALFATE SUSPENSION 500 MG/5L	200 ML	200 ML	48,000	200MLX40
171	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG /5ML EMULSION	200 ML	200 ML	137,000	200MLX40
172	477	CLIDINIUM 2.5 MG+ CHLORDIAZEPOXIDE 5 MG TABLETS	15's	15'sx10	191,000	15'sx10x10
173	478	SODIUM PICOSULPHATE 10 MG TABLETS	10's	10'sx10	131,000	10'sx10x10
174	479	TRICHOLINE CITRATE 550 MG + SORBITOL 7.15 MG SYRUP/5 ML	200 ML	200 ML	77,000	200MLX40
175	480	LEVOSULPIRIDE 75 MG+ ESOMEPRAZOLE 40 MG CAPSULES	10's	10'sx10	69,000	10'sx10x10
176	481	RIFAXIMIN TABLETS BP 40 MG	10's	10'sx10	48,000	10'sx10x10
177	482	LEVOSULPIRIDE 75 MG+ RABEPRAZOLE 20 MG 5 TABLETS	10's	10'sx10	116,000	10'sx10x10
178	483	LOPERAMIDE CAPSULES IP 2 MG	10's	10'sx10	262,000	10'sx10x10
179	484	ESOMEPRAZOLE TABLETS IP 40 MG	10's	10'sx10	324,000	10'sx10x10

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
180	485	PROMETHAZINE TABLETS IP 25 MG	10's	10'sx10	197,000	10'sx10x10
181	486	PANCREATIN 170 MG+ DIMETHICONE 80 MG TABLETS	10's	10'sx10	60,000	10'sx10x10
182	487	DICYCLOMINE 10 MG + DIMETHICONE 40 MG /5 ML SUSPENSION	30 ML	30 MLX10	172,000	30 MLX10X20
183	488	LANSOPRAZOLE CAPSULES IP 15 MG	10's	10'sx10	85,000	10'sx10x10
184	489	SULFASALAZINE TABLETS BP 1000 MG ENTERIC COATED	10's	10'sx10	73,000	10'sx10x10
185	490	SIMETHICONE 15 ML DROPS	15 ML	15 MLX20	120,000	15 MLX20X20
186	491	ITOPRIDE TABLETS 50 MG	10's	10'sx10	34,000	10'sx10x10
187	492	SULFASALAZINE TABLETS BP 500 MG ENTERIC COATED	10's	10'sx10	73,000	10'sx10x10
188	493	ISPAGHULA HUSK IP 50 GM	50 GM	50 GM	47,000	50 GMx50
189	494	ISPAGHULA HUSK IP 100 GM	100 GM	100 GM	47,000	100 GMX100
190	495	FERROUS AMMONIUM CITRATE 160 MG + CYANO COBALAMINE 7.5 MCG + FOLIC ACID 0.5 MG/15ML SYRUP	200 ML	200 ML	480,000	200MLX40
191	496	DYDROGESTERONE TABLETS IP 10 MG	10's	10'sx10	101,000	10'sx10x10
192	497	MIFEPRISTONE 200 MG+ MISOPROSTOL 200 MG TABLETS	1's	1'sx10	100,000	1X10X100
193	498	FERROUS ASCORBATE TABLETS 1.1 MG	10's	10'sx10	253,000	10'sx10x10
194	499	NORETHISTERONE TABLETS IP 5 MG	10's	10'sx10	508,000	10'sx10x10
195	500	LEVO-THYROXINE TABLETS IP 100 MCG	100's in Bottle	100 ML X6	269,000	100 MLX6X20
196	501	BETAMETHASONE TABLETS IP 0.5 MG	20's	20'sx10	2,425,000	20'sx10x10
197	502	DEFLAZACORT TABLETS 6 MG	6's	6'sx10	363,000	6'sx10x10
198	503	METHYL PREDNISOLONE ACETATE INJECTION IP 40 MG/ML	8 ML	8 ML	8,000	8 ML X500
199	504	NANDROLONE DECANOATE INJECTION IP 25MG/ML	2 ML	2 ml x 10	57,000	2 ml x 10 x 100

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
200	505	CARBIMAZOLE TABLETS IP 10 MG	100's in Bottle	100 ML X6	19,000	100 MLX6X20
201	506	LEVO-THYROXINE TABLETS IP 50 MCG	100's in Bottle	100 ML X6	269,000	100 MLX6X20
202	507	CARBIMAZOLE TABLETS IP 5 MG	10's	10'sx10	120,000	10'sx10x10
203	508	LEVETIRACETAM TABLETS 500 MG	10's	10'sx10	376,000	10'sx10x10
204	509	HYDROXYCHLOROQUINE TABLETS IP 200 MG	10's	10'sx10	289,000	10'sx10x10
205	510	PARACETAMOL 325 MG+ TRAMADOL 37.5 MG TABLETS	10's	10'sx10	550,000	10'sx10x10
206	511	PARACETAMOL TABLETS IP 650 MG	15's	15s X 10	1,258,000	15's X 10 X 10
207	512	ACECLOFENAC 100 MG + PARACETAMOL 325 MG + SERRATIOPEPTIDASE 15 MG TABLETS	10's	10'sx10	677,000	10'sx10x10
208	513	PIROXICAM CAPSULES IP 20 MG	10's	10'sx10	292,000	10'sx10x10
209	514	CHYMOTRYPSIN + TRYPSIN (1:6) TABLETS 100K AU	20's	20'sX10	65,000	20'sx10x10
210	515	MEFENAMIC ACID SUSPENSION 100 MG/5 ML	60 ML	60 ML x 10	206,000	60 ML x 10 x 10
211	516	ACECLOFENAC TABLETS SR 200 MG	10's	10'sx10	110,000	10'sx10x10
212	517	THIOLCHICOSIDE 4 MG+ ACECLOFENAC 100 MG TABLETS	10's	10'sx10	75,000	10'sx10x10
213	518	BACLOFEN TABLETS IP 10 MG	10's	10'sx10	81,000	10'sx10x10
214	519	KETOROLAC TABLETS DT 10 MG	10's	10'sx10	167,000	10'sx10x10
215	520	MEFENAMIC ACID 500 MG+ PARACETAMOL 325 MG TABLETS	10's	10'sx10	140,000	10'sx10x10
216	521	TRAMADOL TABLETS SR 100 MG	10's	10'sx10	18,000	10'sx10x10
217	522	ALFACALCIDOL TABLETS 0.25 MG	10's	10'sx10	30,000	10'sx10x10
218	523	NAPROXEN TABLETS IP 500 MG	15's	15'sx10	49,000	15'sx10x10
219	524	LIDOCAINE INJECTION IP 2 % W/V	30 ML VIAL	30 MLX10	96,000	30 MLX10X20

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA,
GURGAON-122016**

**TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016
DT 28-01-2015**

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
220	525	DICLOFENAC 1.16 w/w+ LINCEED OIL3% w/w+ METHYL SALICYLATE 10% w/w+MENTHOL 5% w/w GEL	30 GM	30 GMX20	1,207,000	30 GMX20X10
221	526	CHLORPHENIRAMINE 4 MG+ CODEINE 10 MG/5 ML SYRUP	100 ML	100 ML X6	1,675,000	100 MLX6X20
222	527	AMMONIUM CHLORIDE 50 MG+ CHLORPHENIRAMINE MALETAE 2.5 MG+ DEXTROMETHORPHAN 5 MG+ GUAIFENESIN 50 MG / 5ML SYRUP	100 ML	100 ML X6	258,000	100 MLX6X20
223	528	PARACETAMOL 500 MG+ PHENYLEPHRINE 10 MG+ CHLORPHENIRAMINE 2 MG TABLETS	10's	10'sx10	792,000	10'sx10x10
224	529	LEVOSALBUTAMOL 1.25 MG+ IPRATROPIUM 500 MG RESPULES	5 ML	5 ML X10	1,360,000	5 MLX10X50
225	530	FORMOTERAL 6 MG+ BUDESONIDE 200 MG ROTACAP	30's	30'Sx10	89,000	30'Sx10x10
226	531	GUAIFENESIN 100 MG+ TERBUTALINE 2.5 MG+ BROMHEXINE 8 MG /10 MLSYRUP	100 ML	100 ML X6	196,000	100 MLX6X20
227	532	SALMETEROL 50 MG+ FLUTICASONE 250 MG ROTACAP	30's	30'Sx10	47,000	30'Sx10x10
228	533	BROMHEXINE 4 MG+ DEXTROMETHORPHAN 5 MG+ AMMONIUM CHLORIDE 50 MG /5 ML SYRUP	100 ML	100 ML X6	206,000	100 MLX6X20
229	534	LEVOSALBUTAMOL 200 MG + BECLOMETHASONE 100 MG ROTACAP	30's	30'Sx10	357,000	30'Sx10x10
230	535	TERBUTALINE 2.5 MG + BROMHEXINE 8 MG /10 ML SYRUP	100 ML	100 ML X6	192,000	100 MLX6X20
231	536	PROMETHAZINE 1.5 MG + PHOLCODINE CITRATE 1.5 MG /5ML LINCTUS	60 ML	60 ML x 10	151,000	60 ML x 10 x 10
232	537	SALBUTAMOL 1 MG+ AMBROXOL HYDROCHLORIDE 15 MG/5 ML SYRUP	100 ML	100 ML X6	548,000	100 MLX6X20
233	538	THEOPHYLLINE TABLETS 400 MG	10's	10'sx10	91,000	10'sx10x10
234	539	ACETYLCYSTEINE TABLETS 600 MG	10's	10'sx10	49,000	10'sx10x10
235	540	LEVOSALBUTAMOL 2.5 MG+ BUDESONIDE 2.5 MG REPSULE	5 ML	5 ML X10	209,000	5 MLX10X50
236	541	ACEBROPHYLLINE CAPSULES 100 MG	10's	10'sx10	165,000	10'sx10x10
237	542	SODIUM CHLORIDE 0.65% w/v NASAL DROPS	20 ML	20MLX10	258,000	20MLX10X10
238	543	MENTHOL CINNAMON and PINE OIL SOFT CAPSULES	10's	10'sx10	128,000	10'sx10x10
239	544	FLUTICASONE RESPULE 0.5 MG/2ML	2 ML	2 ml x 10	117,000	2 ml x 10 x 100

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
240	555	DOXOFYLLINE TABLETS IP 400 MG	10's	10'sx10	275,000	10'sx10x10
241	556	MONTELUKAST 10 MG + FEXOFENADINE 120 MG TABLETS	10's	10'sx10	147,000	10'sx10x10
242	557	TIOTROPIUM ROTOCAP 18 MCG	15's	15'sx10	23,000	15'sx10x10
243	558	FLUTICASONE 30 MG+ AZELASTINE 70 MCG NASAL SPRAY	8 ML	8 ML X10	13,000	8 ML X10X50
244	559	SALBUTAMOL 2MG + THEOPHYLLINE 100 MG TABLETS	30's	30'Sx10	285,000	30'Sx10x10
245	560	FLUTICASONE PROPIONATE 0.5 MG PER PUFF NASAL SPRAY	120 MD	120 MD	16,000	120 MDX100
246	561	LEVOSALBUTAMOL 1 MG/5ML SYRUP	100 ML	100 ML X6	137,000	100 MLX6X20
247	562	LORATIDINE TABLETS BP 10 MG	10's	10'sx10	78,000	10'sx10x10
248	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML	10 MLX10	28,000	10 MLX10X20
249	564	FORMOTEROL 12 MG + TIOTROPIUM 18 MG ROTOCAP	15's	15'sx10	19,000	15'sx10x10
250	565	CICLESONIDE 400 MCG+ FORMOTEROL 12 MCG + TIOTROPIUM 18 MCG ROTOCAP	15's	15'sx10	6,000	15'sx10x10
251	566	IPRATROPIUM 250 MCG/ML I:SOLUTION	15 ML	15 ML x20	26,000	15 ML x20 X20
252	567	SALBUTAMOL 100 MCG + IPRATROPIUM 20 MCG /PUFF INHALER	100 MD	1'S	7,000	1'S X100
253	568	SALMETEROL 50 MG+ FLUTICASONE PROPIONATE 250 MG /PUFF INHALER	100 MD	1'S	28,000	1'S X100
254	569	SILDENAFIL TABLETS IP 50 MG	9's	9'Sx10	162,000	9'Sx10x10
255	570	TADALAFIL TABLETS 20 MG	4's	4'sX10	53,000	4'sX10X10
256	571	TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG TABLETS	15's	15'sx10	44,000	15'sx10x10
257	572	COMBINATIONS WITH TETANUS COMPONENT (DIPHTHERIA, TETANUS,PERTUSSIS,POLIOMYELITIS, AND HAEMOPHILUS INFLUENZA) INJECTION	5 ML	5 ML	40,000	5 MLX10X50
258	573	MONOCLONAL ANTI-D GAMAGLOBULIN INJECTION 300 MCG	1 ML	1 MLX10	11,000	1 MLX10X100
259	574	VACCINE RABIES INJECTION 2.5 IU	1 ML	1 MLX10	93,000	1 MLX10X100

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON-122016						
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015						
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
260	575	VACCINE VARICELLA INJECTION 0.5 ML	5 ML	5 ML	15,000	5 ML X 500
261	576	VACCINE HEPATITIS A INJECTION 80 IU	5 ML	5 ML	13,000	5 ML X 500
262	577	VACCINE STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE INJECTION 0.5 ML	0.5 ML	0.5 MLX10	11,000	0.5 MLX10X100
263	578	VACCINE ROTA VIRUS LIVE ORAL	1 ML	1 MLX10	20,000	1 MLX10X100
264	579	CALCIUM PANTOTHENATE 50MG+VIT B12 15 MCG+FOLIC ACID 1.5MG+THIAMINE MONONITRATE 10MG+RIBOFLAVINE 10MG+PYRIDOXINE HCL 3 MG+NIACINAMIDE 100 MG+ASCORBIC ACID 150MG +BIOTIN 100MCG CAPSULES	20's	20'sX10	2,971,000	20'sx10x10
265	580	GINSENG VITAMIN A,B,D,E,CARBOHYDRATE, PROTEIN AND MINERALS CAPSULES	10's	10'sx10	451,000	10'sx10x10
266	581	CALCIUM CARBONATE 500 MG + CALCITRIOL 0.25 MCG + ZINC 7.5 MG	15's	15'sx10	113,000	15'sx10x10
267	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	200 ML	200 ML	184,000	200MLX40
268	583	CYPROHEPTADINE TABLETS IP 4 MG	10's	10'sx10	966,000	10'sx10x10
269	584	CALCIUM CITRATE MALATE 250 MG , VITAMIN D3 100 IU AND FOLINIC ACID 50 MCG TABLETS	30's	30'Sx10	171,000	30'Sx10x10
270	585	VITAMIN D - CHOLECALCIFEROL 60000 IU /1 GM SACHET	1 SACHET	1 GMX25	356,000	1 GMX25X20
271	586	METHYLCOBALAMIN 1500 MCG, L CARTININE L TARTRATE 500 MG, FOLIC ACIDE 1.5 MG TABLETS	10's	10'sx10	100,000	10'sx10x10
272	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS)SYRUP	300 ML	300 ML	172,000	300 ML X20
273	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's	10'sx10	483,000	10'sx10x10
274	589	CALCIUM 500 MG+ CALCITRIOL 0.25 MG TABLETS	15's	15'S X 10	43,000	15'S X 10 X 10
275	590	VITAMIN A,B COMPLEX,D,E INJECTION	10 ML VIAL	10 MLX10	498,000	10 MLX10X20
276	591	METHYLCOBALAMIN 500 MCG INJECTION	1 ML AMPULE	1 MLX10	115,000	1 MLX10X100
277	592	L-LYSINE + MULTIVITAMINS SYRUP	200 ML	200 ML	207,000	200MLX40
278	593	NICOTINAMIDE 200 MG+ FOLIC ACID 15 MG + CYANOCOBALAMIN 0.5 MCG INJECTION	10 ML	10 MLX10	109,000	10 MLX10X20

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA,
GURGAON-122016**

**TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016
DT 28-01-2015**

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Approx tender Qty in units	Packing per carton specification
279	594	GLUCOSE D POWDER	100 GM	100 GM	22,000	100 GMX40
280	595	THIAMINE 100 MG+ PYRIDOXINE HCl 50 MG + CYANOCOBALAMIN 1000 MCG INJECTION	2 ML	2 ml x 10	602,000	2 ml x 10 x 100
281	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15 ML	15 ML x20	40,000	15 ML x20 X20
282	597	VITAMIN B6 TABLETS IP 5 MG	10's	10'sx10	147,000	10'sx10x10
283	598	PREGABALIN 75 MG+ METHYLCOBALAMIN 1500 MCG TABLETS	10's	10'sx10	120,000	10'sx10x10
284	599	PREGABALIN TABLETS 75 MG	10's	10'sx10	120,000	10'sx10x10
<div> <div>Date:</div> <div>Place:</div> <div>Seal:</div> </div> <div> <div>Signature:</div> <div>Name:</div> <div>Designation:</div> </div>						

ANNEXURE-X

Ref. Clause No.14.1

SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES

GENERAL SPECIFICATIONS

1. Strips of Aluminum foils should be gauge 04.
2. Aluminum foils s back material for blisters should be gauge 025.
3. The rigid PVC used in blister packing should be of not less than 250 micron
4. All glass bottles should be new neutral glass. Pet bottles so accepted as per drug laws stipulation.
5. Ointments should be packed in lacquerized Aluminum Tubes or Lami tubes.
6. Small Tablets packed in blisters should be packed to facilitate easy removal of the tablet without breaking / crushing.
7. Specification of outer cartons are as given in the Schedule (Annexure-X)
8. In case of any conflict between Carton specifications and packets per carton specification (Last column of this table), the specification of the packets / carton shall prevail.
9. All plastic containers should be made of virgin grade plastics
10. Injection in vials should have a flip-off seals.
11. The strips shall be aluminum strip / blisters with aluminum foil back.
12. The minimum diameters of each tablets should be of 6.4mm
13. The outer carton should be of white board with a minimum of 300 GSM with laminated packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350GSM.
14. All liquid oral preparations to be provided with a measuring plastic cup, fitted over the cap of the bottle.
15. All primary packaging should have BPPI toll free number 1800 180 8080

1.	CORRUGATED BOXES
----	-------------------------

	1. No corrugate package should weigh more than 15 kgs (i.e. product + inner carton + corrugated box). 2. All Corrugated boxes should be of 'A' grade paper i.e. Virgin. 3. All items should be packed only in first hand boxes only.
2.	FLUTE The corrugated boxes should be of narrow flute.
3.	JOINT Every box should be preferably single joint and not more than two joints.
4.	STITCHING Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.
5.	FLAP The flaps should uniformly meet but should not over lap each other. The flap when turned by 45 - 60° should not crack.
6.	TAPE Every box should be sealed with gum tape running along the top and lower opening.
7.	CARRYSTRAP: Every box should be strapped with two parallel nylon carry straps (they should intersect).
8.	LABEL The product label on the carton should be large at least 15 cms x 10 cms dimension. It should carry the correct technical name, strength or the product, date of manufacturing, date of expiry, quantity packed and net weight of the box.
9.	OTHERS No box should contain mixed products or mixed batches of the same product.

II. SPECIFICATION FOR CORRUGATED BOXES HOLDING TABLETS / CAPSULES / PESSARIES

(1) The box should not weigh more than 7-8 kgs. The grammage of outer box should be 150 gsm and inside partition / lining should be 120 gsm.

(2) The box should be of 5 ply with bursting strength of 9 Kg / Cm²

III. SPECIFICATIONS FOR OINTMENT / CREAM / GELS PACKED IN TUBES:

(1) No corrugate box should weigh more than 7-8 Kgs.

(2) Every Ointment tube should be individually packed in carton and then packed in 20's in a grey board box, which may be packed in a corrugated box.

- (3) Grammage: Outer box should be 150 gsm inside partition /
 Lining should be 120gsm.

IV. SPECIFICATIONS FOR INJECTABLE (IN VIALS AND AMPOULES)

- (1) Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 kgs.
- (2) C.B. for vials should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 7 ply, while CB. For ampoules should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 5 ply.
- (3) Bursting strength for CB boxes for
- | | |
|----------|--|
| i. Vials | : Note less than 13 Kg/Cm ² |
| ii. Amp | : Note less than 9 Kg/Cm ² |
- (4) In the case of 10 ml Ampoules 100 or 50 ampoules may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.
- (5) If the vial is packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with center pad.
- (6) In case of ampoules every grey board box should carry 5 amps. Cutters placed in a polythene bag.
- (7) Vials of eye and ear drops should be packed in an individual carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

Annexure-XI

Ref. Clause No.10.2

AGREEMENT

THIS AGREEMENT made theday of2015 Between Bureau of Pharma Public Sector Undertakings of India, IDPL Complex, Old-Delhi Gurgaon Road, Dundahera, Gurgaon 122016 (Haryana)

(Name of purchaser) of.....(Country of Purchaser) (here in after “the Purchaser”) of the one part and(Name of Supplier) of(City and Country of Supplier) (herein after called “the Supplier”) of the other part :

WHEREAS the Purchaser is desirous that certain Goods and ancillary services viz; Supply of Drugs and Medicines in the tender Reference No. BPPI/DRUGS/016/2015 (Brief Description of Goods and Services) and has accepted a bid by the Supplier for the supply of those goods and services for the sum of(Contract Price in Words and Figures(hereinafter called “the Contract Price”).

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to, and they shall be deemed to form and be read and construed as part of this agreement.
2. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz
 - a. The Letter of Acceptance issued by the purchaser.
 - b. The Notice Inviting Tender
 - c. The supplier’s bid including enclosures, annexures, etc.
 - d. The Terms and Conditions of the Contract

- e. The Schedule of Requirement
 - f. The Technical Specification
 - g. Any other document listed in the supplier's bid and replies to queries, clarifications issued by the purchaser, such confirmations given by the bidder which are acceptable to the purchaser and the entire Addendum issued as forming part of the Contract.
3. In consideration of the payments to be made by the Purchaser to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Purchaser to provide, the goods and services and to remedy defects therein in conformity in all respects with the provisions of the Contract. .
 4. The purchaser hereby covenants to pay the Supplier in consideration of the provision of the goods and services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

Brief particulars of the goods and services which shall be supplied / provided by the Supplier are as under:

S.No.	Drug Code	Brief Description of Goods & Services	Tender Qty in Unit*	Unit Price	CST/VAT in %	Total (B+C)	Total value inclusive ST/VAT (A x D)
			(A)	(B)	(C)	(D)	
Total Contract Value							

- * **Tender quantity indicated here is tentative and may vary subjected to various terms and conditions of the tender.**
- * **Excise duty as applicable on MRP to be intimated by BPPI at the time of placing orders will be payable as per prevailing excise duty rates.**

DELIVERY SCHEDULE

Supply shall commence within 30/45 days and shall complete within 60 days from the date of purchase order.

IN WITNESS where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, Sealed and Delivered by the

Said.....(For the Purchaser)

Name

Address

Designation

In the presence of witness.....

Signature

Name

Address

Designation

Signed, Sealed and Delivered by the

Said.....(For the Supplier)

Name

Address

Designation

In the presence of witness

Signature

Name

Address Designation

Annexure-XII

Ref. Clause No.10.1

Performance Security Bank Guarantee

(unconditional)

To: Bureau of Pharma Public Sector Undertakings of India, (Name of purchaser) IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

WHEREAS.....(Name of the Supplier) herein called “the Supplier” has undertaken, in pursuance of Tender BPPI/DRUGS/016/2015 dated **28.01.2015** to supply of **Drugs and Medicines for the year 2015-17**, (Description of Goods and Services) hereinafter called “the Contract”.

AND WHEREAS it has been stipulated by you in the said Contract that the Supplier shall furnish you with a Bank Guarantee for the sum specified therein as security for compliance with the Supplier’s performance obligations in accordance with the Contract.

AND WHEREAS we have agreed to give the Supplier a Guarantee

THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, upto a total of(Amount of the Guarantee in Words and Figures) and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the Contract and without cavil or argument., any sum or sums within the limit of(Amount of the Guarantee in Words and Figures) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

This guarantee is valid until theday of.....2017.

Signature and Seal of Guarantors

.....
.....
.....

Date.....2015

Address.....

.....

Annexure – XIII

Ref. Clause No.4.1 (o)

DETAILS OF MANUFACTURING /IMPORTING UNIT

Sl.No.	Details	
1.	Name of the Tenderer & Full Address	
2.	PAN Number	
3.	TIN Number	
4.	Phone Nos.	
5.	Fax	
6.	E-Mail ID	
7.	Date of Inception	
8.	Licence No. & Date	
9.	Issued By	
10.	Valid Upto	

Details of Installed Production Capacity for 1 year

(In Terms of Unit Packs)

S.No.	Details	
1.	Tablets	
2.	Capsules	
	a) General	
	b) Beta-Lactum	
3.	Injections	
	a) Ampoules	
	b) Vials	
	c) I.V. Fluids	
	d) Sterile Powder	
4.	Liquids	
	a) Suspension	
	b) Syrups	
	c) Drops	
5.	Ointment	
6.	Powders	
7.	Antiseptics / Disinfectants	
8.	Name & designation of the authorized Signatory	
9.	Specimen signature of the authorized Signatory	

* The details of manufacturing unit shall be for the premises where items quoted are actually manufactured.

Annexure – XIV

Ref. clause 4.1 (r)

LIST OF ITEMS QUOTED

Sl.No.	Details																			
1.	Name of the firm and address (As given in Drug licence)																			
2.	Drug Licence No. in form 25 & 28 Or import Licence No.																			
3.	Date of issue & validity																			
4.	GMP certificate obtained on																			
5.	Non-conviction Certificate Obtained on																			
6.	Market standing Certificate Obtained on																			
7.	Details of Endorsement for all products quoted :																			
<table border="1" style="width: 100%; border-collapse: collapse;"><thead><tr><th style="width: 10%;">Sl.No.</th><th style="width: 10%;">Drug Code</th><th style="width: 20%;">Drug Name</th><th style="width: 20%;">Specifications IP/BP/USP</th><th style="width: 20%;">Date of Endorsement obtained from the State Drugs Controller</th><th style="width: 20%;">Whether Endorsement is in Generic or Trade Name</th></tr></thead><tbody><tr><td>1.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2.</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>			Sl.No.	Drug Code	Drug Name	Specifications IP/BP/USP	Date of Endorsement obtained from the State Drugs Controller	Whether Endorsement is in Generic or Trade Name	1.						2.					
Sl.No.	Drug Code	Drug Name	Specifications IP/BP/USP	Date of Endorsement obtained from the State Drugs Controller	Whether Endorsement is in Generic or Trade Name															
1.																				
2.																				
Authorised signatory: Date:																				

Annexure-XV

Ref. clause 16.2

MANDATE FORM

Sl.No.	Details Required	
1.	Company Name	
2.	Postal Address of the Company	
	Telephone No.	
	Fax No.	
	E-mail ID	
3.	Name of the Managing Director / Director / Manager	
	Mobile No. / Phone No	
	E-mail ID	
4.	Name and Designation of the authorized company official	Name: Designation:
	Mobile No.	
	E-mail ID	
5.	Bank Details	
	a) Name of the Bank	
	b) Branch Name & address	
	c) Branch Code No.	
	d) Branch Manager Mobile No.	
	e) Branch Telephone no	
	f) Branch E-mail ID	
	g) 9 digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank	
	h) IFSC Code of the Branch	
	i) Type of Account (Current / Savings)	
	j) Account Number (as appear in cheque book)	

(In lieu of the bank certificate to be obtained, please **attach the original cancelled cheque** issued by your bank for verification of the above particulars).

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold Bureau of Pharma Public Sector Undertakings of India (BPPI) responsible. I have read the conditions of the tender / agreement entered and agree to discharge the responsibility expected of me / from the company as a tenderer / successful tenderer.

Date:

Company Seal

Signature

Place:

(Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Signature of the authorized official of the bank

Bank Seal with address:

Annexure – XVI

Ref. Clause 4.1 (s)

CHECK-LIST

COVER – A

S.No.	Check List	Page no	YES	NO
1.	Checklist - Annexure – XVI			
2.	EMD in the form of DD shall be kept in an Envelope as per Annexure-V SSI certificate For exemption			
3.	Undertaking of in form Annexure-VI			
4.	Documentary evidence for the constitutions of the company / concern			
5.	Duly attested photocopy of License for the Product duly approved by the Licensing Authority for each and every product quoted			
6.	Duly attested photocopy of Import License, if Imported and whole sale Drug license			
7.	The instruments such as power of attorney, Resolution of board etc.,			
8.	Authorization letter nominating a responsible Person of the tenderer to transact the business with the Tender inviting Authority			
9.	Market Standing Certificate issued by the Licensing Authority			
10.	True copy of record of manufacture to establish 3 years market standing			
11.	Non Conviction Certificate issued by the licensing authority			
12.	Good Manufacturing Practices Certificate			
13.	Annual Turnover Statement for 3 Years (Annexure – VIII)			
14.	Copies of balance sheet & profit loss account for three years			
15.	Annexure – I (Sales Tax clearance certificate)			
16.	Annexure – II (Undertaking for embossment of logo)			
17.	Annexure-II (A) (Undertaking for embossment of logo)			
18.	Declaration Form in Annexure-III along with enclosure			
19.	Proforma for Performance Statement			

	(Annexure-VII)			
20.	Details of Manufacturing / Importing Unit in Annexure-XIII			
21.	WHO certificates if any			
22.	Details of Technical personnel employed in the manufacture and testing			
23.	List of items quoted without rates (Annexure – XIV)			
24.	Mandate Form (Annexure – XV)			
25.	The Tender document signed by the tenderer in all pages with office seal			

Cover “B”

S.No.	Check List	YES	NO
1.	Annexure XVII duly filled		
2.	Annexure XVIII duly filled		
3.	Pen drive/compact disc having duly filled annexures XVII and XVIII		

Name and signature of authorised signatory(with company seal)

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016								
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015							Annexure XVII	
Landed Price								
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)		(6)		(7)
1	5	ASPIRIN TABLETS IP 150 MG	14's	466,000				
2	6	DICLOFENAC 50 MG+ PARACETAMOL 325 MG+ CHLORZOXAZONE 500 MG TABLETS	10's	75,000				
3	40	AMOXYCILLIN 250 MG+ CLOXACILLIN 250 MG CAPSULES	9's	52,000				
4	60	CEFOTAXIME SODIUM 250 MG & SULBACTAM SODIUM 125 MG INJECTION	1 Vial & wfi	75,000				
5	83	CIPROFLOXACIN 250 MG+ TINIDAZOLE 300 MG TABLETS	10's	96,000				
6	89	CO-TRIMOXAZOLE TABLETS IP (160 MG + 800 MG)	10's	120,000				
7	98	NORFLOXACIN 400 MG + TINIDAZOLE 600 MG FILM COATED TABLETS	10's	20,000				
8	109	VANCOMYCIN INJECTION IP 500 mg	VIAL & WFI	2,00,000				
9	112	BECLOMETHASONE IP 0.025% w/w+ CLOTRIMAZOLE IP 1% w/w+ GENTAMYCIN IP 0.1% w/w CREAM	15 GM	2,70,000				
10	117	CHLORHEXIDINE MOUTHWASH IP 2 % w/v	160 ML	111,000				
11	142	INSULIN INJECTION IP 40 IU/ML (Insulin Human Recombinant)	10 ML VIAL	136,000				
12	143	BIPHASIC INSULIN ASPART INJECTION IP 100 IU/ML (30:70)	VIAL	47,000				
13	144	METFORMIN HYDROCHLORIDE TABLETS IP SR 1000 MG	10's	9,000				
14	153	CISPLATIN INJECTION IP 10 MG	VIAL	100,000				
15	165	CIPROFLOXACIN INJECTION IP 2MG/ML	100 ML	36,000				
16	170	MANNITOL INJECTION IP 20% w/v	100 ML	100,000				
17	172	METRONIDAZOLE INJECTION IP 5 MG / ML	100 ML	120,000				

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
18	178	ALBENDAZOLE 400 MG + IVERMECTIN 6 MG TABLETS	1's	177,000				
19	181	TRICHOLINE CITRATE 275 MG+ CYPROHEPTADINE HCl 2 MG/5ml SYRUP	200 ML	202,000				
20	188	ANTACID TABLETS [DRIED Al(OH) ₃ + Mg(OH) ₂ + SIMETHICONE (250MG + 250MG + 50MG)	10's	4,000				
21	191	FAMOTIDINE TABLETS IP 20 MG	10's	485,000				
22	192	FAMOTIDINE TABLETS IP 40 MG	14's	1,010,000				
23	196	LACTOBACILLUS SPOROGENES 60 MILLION SPORES TABLETS	10's	243,000				
24	208	ONDENSETRON INJECTION IP 2 mg/ml	2 ML	1,20,000				
25	216	RANITIDINE INJECTION IP 50 MG/ 2ML	2 ML	760,000				
26	218	RANITIDINE TABLETS IP 300 MG FILM COATED	10's	1,723,000				
27	223	PYRIDOXINE HCl 10 MG+ DOXYLAMINE 10 MG + FOLIC ACID 2.5 MG TABLETS	30's	100,000				
28	225	IRON HYDROXIDE POLYMALTOSE COMPLEX EQ TO ELEMENTAL IRON 50 MG+ FOLIC ACID 0.5 MG /15 ML SYRUP	200 ML	1,00,000				
29	230	VITAMIN B COMPLEX WITH ZINC CAPSULES	20's	517,000				
30	231	VITAMIN B1 10MG, B2 10 MG, NIACINAMIDE 45 MG, CALCIUM PANTOTHENATE 50 MG, B6 3 MG AND B12 15 MCG TABLETS	10's	1,924,000				
31	232	VITAMIN B-VOMPLEX NFI Syrup	200 ML	2,00,000				
32	235	BUDESONIDE RESPULES 0.5 MG	2 ML	912,000				
33	241	COUGH SYRUP DEXTROMETHORPHAN HBR 10 mg+ CPM 10 MG /10 ML SYRUP	100 ml	1,85,000				
34	242	COUGH SYRUP [CPM 3 MG. + ALU.CHL. 110 MG. +SOD. CIT. 46 MG. + MENTHOL 0.9 MG /5 ML]	110 ML	120,000				

Date Place: _____ Name: _____ Signature: _____
 Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
35	243	COUGH SYRUP [DIPHEN.14 MG. + ALU.CHL.135 MG. + SOD.CIT.57 MG. + MENTHOL 0.9 MG/5ML]	110 ML	120,000				
36	244	THEOPHYLLINE 25.3 MG+ ETOPHYLLINE 84.6MG INJECTION 2 ML	2 ML	1,746,000				
37	253	PHENIRAMINE TABLETS IP 25 MG	15's	1,298,000				
38	255	SALBUTAMOL INHALATION IP 100 µg	200 MD	182,000				
39	270	ASPIRIN 75 MG + CLOPIDOGREL 75 MG TABLETS	10's	439,000				
40	278	FRUSEMIDE INJECTION IP (10 MG/ ML)	2 ML	107,000				
41	285	AMLODIPINE 5 MG + LISINOPRIL 5 MG TABLETS	15's	103,000				
42	299	TELMISARTAN TABLETS IP 20 mg	10's	2,00,000				
43	302	TRANEXAMIC ACID 500 MG/5 ML	5 ML AMPULE	2,10,000				
44	306	PRIMAQUINE TABLETS IP 15 MG	7's	120,000				
45	323	FLUNARZINE TABLETS 10MG	10's	200,000				
46	324	FLUNARZINE TABLETS 5MG	10's	95,000				
47	327	PHENYTOIN TABLETS IP 100 MG	100's in Bottle	125,000				
48	329	PREDNISOLONE TABLETS IP 5 MG	15's	1,573,000				
49	331	THYROXINE SODIUM TABLETS IP 50 µg	10's	210,000				
50	334	DEXAMETHASONE INJECTION IP 4 MG/ML	2 ML	1,112,000				
51	338	ATROPINE SULPHATE INJECTION IP 0.6MG/ ML	1 ML	100,000				
52	341	CARBOXY METHYL CELLULOSE EYE DROPS IP 0.5% w/v	10 ML	100,000				
53	356	LIGNOCAINE INJECTION IP 2% w/v	20 ML VIAL	2,00,000				
54	359	TETANUS VACCINE (Adsorbed) IP	AMP 0.5 ML	1,160,000				
55	360	MIFEPRISTONE TABLETS 200 MG	1's	60,000				
56	361	OXYTOCIN INJECTION 5 iu/ ml	1 ML	10,00,000				
57	362	BIPHASIC ISOPHANE INSULIN INJECTION IP 40 IU/ML (50:50)	10 ML VIAL	340,000				

Date Place: _____ Name: _____ Signature: _____
 Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
58	363	GLARGINE 100 IU INJECTION	CARTRIDGE 3 ML	72,000				
59	364	GLIMEPIRIDE 2 MG + METFORMIN HYDROCHLORIDE 500 MG TABLETS SR	15's	795,000				
60	365	GLICLAZIDE 80 MG + METFORMIN HYDROCHLORIDE TABLETS 500 MG	15's	666,000				
61	366	GLIPIZIDE 5 MG + METFORMIN HYDROCHLORIDE 500 MG TABLETS	10's	1,309,000				
62	367	VOGLIBOSE TABLETS IP 0.3 MG	10's	380,000				
63	368	GLICLAZIDE TABLETS SR 60 MG	14's	55,000				
64	369	ACARBOSE TABLETS IP 50 MG	10's	46,000				
65	370	NEUTRAL PROTAMINATED HAGEDORN INJECTION 40 IU	10 ML VIAL	40,000				
66	371	VOGLIBOSE TABLETS IP 0.2 MG	10's	243,000				
67	372	METFORMIN HYDROCHLORIDE TABLETS IP SR 500 MG	10's	9,000				
68	373	ARTESUNATE INJECTION 60 MG	1 ML	99,000				
69	374	ARTEMETHER 80 MG + LUMEFANTRINE 480 MG TABLETS	6's	91,000				
70	375	QUININE SULPHATE TABLETS IP 300 MG FILM COATED TABLETS	10's	44,000				
71	376	IMIPENEM AND CILASTATIN INJ IP (500MG+500MG)	20 ML	36,000				
72	377	CLINDAMYCIN CAPSULES IP 300 MG	10's	22,000				
73	378	RIFAMPICIN, ISONIAZIDE, ETHAMBUTOL and PYRAZINAMIDE TABLETS IP (450MG+300MG+800MG+750MG) KIT	1's	655,000				
74	379	RIFAMPICIN and ISONIAZIDE TABLETS IP (450 MG+300 MG)	10's	144,000				
75	380	CLARITHROMYCIN TABLETS IP 500 MG	4's	42,000				

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
76	381	CEFIXIME 200 MG + OFLOXACIN 200 MG TABLETS	10's	537,000				
77	382	LINEZOLID TABLETS IP 600 MG	10's	95,000				
78	383	CEFPODOXIME 200 MG+ CLAVULANIC ACID 125 MG TABLETS	6's	286,000				
79	384	ITRACONAZOLE CAPSULES 100 MG	4's	139,000				
80	385	CEFIXIME 200 MG + CLAVULANIC ACID 125 MG TABLETS	10's	170,000				
81	386	DIETHYLCARBAMAZINE TABLETS IP 50 MG	30's	172,000				
82	387	TERBINAFINE 250 MG TABLETS	7's	206,000				
83	388	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG and ETHAMBUTOL TABLET IP 800MG	1's	484,000				
84	389	PENICILLIN G 400000 IU TABLETS	6's	684,000				
85	390	ETHAMBUTOL TABLETS IP 800 MG	10's	129,000				
86	391	MOXIFLOXACIN TABLETS 400 MG	5's	134,000				
87	392	GRISEOFULVIN TABLETS IP 250 MG	10's	220,000				
88	393	ACICLOVIR TABLETS IP 800 MG	5's	47,000				
89	394	PYRANTEL PAMOATE ORAL SUSPENSION IP 250 MG/10 ML	10 ML	237,000				
90	395	CEFUROXIME 500 MG+ CLAVULANIC ACID 125 MG TABLETS	6's	68,000				
91	396	AMPHOTERICIN B INJECTION 50 MG	20 ML	4,000				
92	397	OXYTETRACYCLINE CAPSULES IP 250 MG	8's	486,000				
93	398	RIFAMPICIN TABLETS IP 450 MG	10's	28,000				
94	399	RIFAMPICIN, ISONIAZIDE and PYRAZINAMIDE TABLETS IP (100MG+50MG+300MG)	10's	76,000				
95	400	KETOCONAZOLE TABLETS IP 200 MG	10's	12,000				

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
96	401	AMOXYCILLIN and POTASSIUM CLAVULANATE TABLETS IP (250MG+150MG)	6's	432,000				
97	402	AMOXYCILLIN and POTASSIUM CLAVULANATE TABLETS IP (875MG+125MG)	6's	1,488,000				
98	403	CLINDAMYCIN INJ IP 300 MG/2 ML	2 ML	38,000				
99	404	LINEZOLID INFUSION 300 MG/200 ML	200 ML	577,000				
100	405	OFLOXACIN INFUSION IP 200 MG /100 ML	100 ML	80,000				
101	406	ACICLOVIR INTRAVENOUS INFUSION IP 500 MG/VIAL	VIAL	98,000				
102	407	IVERMECTIN TABLETS 12 MG	10's	120,000				
103	408	BENZYL PENICILLIN INJECTION IP 0.6 MILLION UNITS	VIAL	120,000				
104	409	BENZYL PENICILLIN INJECTION IP 1.2 MILLION UNITS	VIAL	120,000				
105	410	TRASTUZUMAB INJECTION 400 MG	1's	1,000				
106	411	BEVACIZUMAB INJECTION 100 MG	1's	1,000				
107	412	AZATHIOPRINE TABLETS IP 50 MG	10's	57,000				
108	413	METHOTREXATE TABLETS IP 7.5 MG	10's	35,000				
109	414	TRANEXAMIC ACID 500 MG+ MEFENAMIC ACID 250 MG TABELTS	10's	125,000				
110	415	GLYCERYL TRINITRATE TABLETS IP 250 µg	25's	194,000				
111	416	PRAZOSIN TABLETS IP 5 MG	15's	137,000				
112	417	TELMISARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	15's	675,000				
113	418	ROSUVASTATIN TABLETS IP 20 MG	10's	166,000				
114	419	HEPARIN SODIUM 50 IU/20 GM OINTMENT	20 GM	139,000				
115	420	ATORVASTATIN 10 MG+ CLOPIDOGREL 75 MG TABLETS	10's	63,000				
116	421	NEBIVOLOL HYDROCHLORIDE TABLETS IP 5 MG	10's	234,000				

Date Place: _____ Name: _____ Designation: _____ Signature: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
117	422	TORSEMIDE TABLETS 10 MG	15's	210,000				
118	423	BISOPROLOL TABLETS 5 MG	10's	121,000				
119	424	CARVEDILOL TABLETS IP 3.125 MG	10's	258,000				
120	425	DILTIAZEM TABLETS IP SR 90 MG	10's	65,000				
121	426	ACENOCOUMAROL TABLETS IP 2 MG	30's	26,000				
122	427	S-AMLODIPINE TABLETS IP 2.5 MG	10's	366,000				
123	428	DIGOXIN TABLETS IP 250 µg	10's	374,000				
124	429	ATORVASTATIN 10 MG+ FENOFIBRATES 160 MG TABLETS	15's	190,000				
125	430	AMIODARONE TABLETS IP 200 MG	10's	43,000				
126	431	RAMIPRIL and HYDROCHLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	10's	60,000				
127	432	OLMESARTAN TABLETS 40 MG	10's	185,000				
128	433	ISOSORBIDE-5-MONONITRATE TABLETS IP 30 MG	30's	42,000				
129	434	PROPRANOLOL TABLETS IP 40 MG	10's	115,000				
130	435	ROSUVASTATIN 10 MG + FENOFIBRATES 160 MG TABLETS	10's	99,000				
131	436	TELMISARTAN 40 MG+ CHLORTHALIDONE 12.5 MG TABLETS	10's	124,000				
132	437	NIFEDIPINE SUSTAINED RELEASE TABLETS IP 20 MG	10's	324,000				
133	438	INDAPAMIDE TABLETS IP 1.5 MG	10's	50,000				
134	439	OLMESARTAN 40 MG + HYDROCHLORTHIAZIDE 12.5 MG TABLETS	10's	146,000				
135	440	METOPROLOL 50 MG + AMLODIPINE 5 MG TABLETS	7's	400,000				
136	441	LOSARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	10's	278,000				
137	442	FENOFIBRATE CAPSULES IP 150 MG	10's	42,000				
138	443	ISOSORBIDE DINITRATE TABLETS IP 5 MG	50's	122,000				

Signature: _____

Date Place: _____

Name: _____

Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
139	444	ENALAPRIL 10 MG + HYDROCLORTHIAZIDE 25 MG TABLETS	30's	24,000				
140	445	OLMESARTAN 5 MG+ AMLODIPINE 20 MG TABLETS	10's	112,000				
141	446	AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE 12.5 MG TABLETS	10's	173,000				
142	447	MOXONIDINE TABLETS 0.3 MG	10's	55,000				
143	448	AMLODIPINE 5 MG+ RAMIPRIL 5 MG TABLETS	10's	15,000				
144	449	SPIRONOLACTONE TABLETS IP 25 MG	15's	67,000				
145	450	LABETALOL TABLETS IP 100 MG	10's	25,000				
146	451	STREPTOKINASE INJECTION IP 1500000 IU	10 ML	2,000				
147	452	WARFARIN TABLETS IP 5 MG	10's	76,000				
148	453	BISOPROLOL 5 MG+ HYDROCHLOROTHIAZIDE 6.25 MG TABLETS	10's	22,000				
149	454	VALSARTAN TABLETS IP 80 MG	10's	14,000				
150	455	VERAPAMIL TABLETS IP 80 MG	10's	120,000				
151	456	ATORVASTATIN TABLETS IP 40 MG	10's	432,000				
152	457	TORSEMIDE TABLETS 20 MG	10's	210,000				
153	458	LABETALOL INJECTION IP 5 MG/ML	4 ML VIAL	25,000				
154	459	HYDROQUINONE 2 MG + MOMETASONE 0.1 MG+ TRETINOIN 0.025 % CREAM	20 GM	402,000				
155	460	TERBINAFINE 1 MG + CLOBETASOL 0.05 MG + OFLOXACIN 0.75 MG + ORNIDAZOLE 2 % w/w CREAM	15 GM	604,000				
156	461	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM	1,513,000				
157	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12w/w+3% w/w)	30 GM	701,000				
158	463	MUPIROCIN OINTMENT IP 2 % w/w	5 GM	352,000				

Signature: _____

Date Place: _____

Name: _____

Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
159	464	DICYCLOMINE 10 MG + PARACETAMOL 325 MG + TRAMADOL 50 MG CAPSULES	8's	1,287,000				
160	465	DOMPERIDONE 30 MG+ PANTOPRAZOLE 40 MG CAPSULES	10's	895,000				
161	466	URSODEOXYCHOLIC ACID TABLETS IP 300 MG	10's	236,000				
162	467	DICYCLOMINE 10 MG+ MEFENAMIC ACID 250 MG TABLETS	10's	740,000				
163	468	ENTEROGERMINA ORAL SUSPENSION 200 MILLION/ 5 ML	100 ML	425,000				
164	469	HEPATIC PROTECTORS SYRUP	200 ML	640,000				
165	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ML	234,000				
166	471	OXETACAINE 10 MG+ ALUMINIUM 291 MG + MAGNESIUM 98 MG /5 ML GEL	200 ML	211,000				
167	472	DOMPERIDONE 30 MG+ ESOMEPRAZOLE 40 MG CAPSULE	10's	133,000				
168	473	LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40 MG CAPSULE	10's	56,000				
169	474	DOXYLAMINE 10 MG+ PYRIDOXINE HCl 10 MG TABLETS	30's	142,000				
170	475	SUCRALFATE SUSPENSION 500 MG/5L	200 ML	48,000				
171	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG /5ML EMULSION	200 ML	137,000				
172	477	CLIDINIUM 2.5 MG+ CHLORDIAZEPOXIDE 5 MG TABLETS	15's	191,000				
173	478	SODIUM PICOSULPHATE 10 MG TABLETS	10's	131,000				
174	479	TRICHOLINE CITRATE 550 MG + SORBITOL 7.15 MG SYRUP/5 ML	200 ML	77,000				
175	480	LEVOSULPIRIDE 75 MG+ ESOMEPRAZOLE 40 MG CAPSULES	10's	69,000				
176	481	RIFAXIMIN TABLETS BP 40 MG	10's	48,000				

Signature: _____

Date Place: _____

Name: _____

Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
177	482	LEVOSULPIRIDE 75 MG+ RABEPRAZOLE 20 MG 5 TABLETS	10's	116,000				
178	483	LOPERAMIDE CAPSULES IP 2 MG	10's	262,000				
179	484	ESOMEPRAZOLE TABLETS IP 40 MG	10's	324,000				
180	485	PROMETHAZINE TABLETS IP 25 MG	10's	197,000				
181	486	PANCREATIN 170 MG+ DIMETHICONE 80 MG TABLETS	10's	60,000				
182	487	DICYCLOMINE 10 MG + DIMETHICONE 40 MG /5 ML SUSPENSION	30 ML	172,000				
183	488	LANSOPRAZOLE CAPSULES IP 15 MG	10's	85,000				
184	489	SULFASALAZINE TABLETS BP 1000 MG ENTERIC COATED	10's	73,000				
185	490	SIMETHICONE 15 ML DROPS	15 ML	120,000				
186	491	ITOPRIDE TABLETS 50 MG	10's	34,000				
187	492	SULFASALAZINE TABLETS BP 500 MG ENTERIC COATED	10's	73,000				
188	493	ISPAGHULA HUSK IP 50 GM	50 GM	47,000				
189	494	ISPAGHULA HUSK IP 100 GM	100 GM	47,000				
190	495	FERROUS AMMONIUM CITRATE 160 MG + CYANO COBALAMINE 7.5 MCG + FOLIC ACID 0.5 MG/15ML SYRUP	200 ML	480,000				
191	496	DYDROGESTERONE TABLETS IP 10 MG	10's	101,000				
192	497	MIFEPRISTONE 200 MG+ MISOPROSTOL 200 MG TABLETS	1's	100,000				
193	498	FERROUS ASCORBATE TABLETS 1.1 MG	10's	253,000				
194	499	NORETHISTERONE TABLETS IP 5 MG	10's	508,000				
195	500	LEVO-THYROXINE TABLETS IP 100 MCG	100's in Bottle	269,000				
196	501	BETAMETHASONE TABLETS IP 0.5 MG	20's	2,425,000				
197	502	DEFLAZACORT TABLETS 6 MG	6's	363,000				
198	503	METHYL PREDNISOLONE ACETATE INJECTION IP 40 MG/ML	8 ML	8,000				

Signature: _____

Date Place: _____

Name: _____

Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
199	504	NANDROLONE DECANOATE INJECTION IP 25MG/ML	2 ML	57,000				
200	505	CARBIMAZOLE TABLETS IP 10 MG	100's in Bottle	19,000				
201	506	LEVO-THYROXINE TABLETS IP 50 MCG	100's in Bottle	269,000				
202	507	CARBIMAZOLE TABLETS IP 5 MG	10's	120,000				
203	508	LEVETIRACETAM TABLETS 500 MG	10's	376,000				
204	509	HYDROXYCHLOROQUINE TABLETS IP 200 MG	10's	289,000				
205	510	PARACETAMOL 325 MG+ TRAMADOL 37.5 MG TABLETS	10's	550,000				
206	511	PARACETAMOL TABLETS IP 650 MG	15's	1,258,000				
207	512	ACECLOFENAC 100 MG + PARACETAMOL 325 MG + SERRATIOPEPTIDASE 15 MG TABLETS	10's	677,000				
208	513	PIROXICAM CAPSULES IP 20 MG	10's	292,000				
209	514	CHYMOTRYPSIN + TRYPSIN (1:6) TABLETS 100K AU	20's	65,000				
210	515	MEFENAMIC ACID SUSPENSION 100 MG/5 ML	60 ML	206,000				
211	516	ACECLOFENAC TABLETS SR 200 MG	10's	110,000				
212	517	THIOLCHOLCHOSIDE 4 MG+ ACECLOFENAC 100 MG TABLETS	10's	75,000				
213	518	BACLOFEN TABLETS IP 10 MG	10's	81,000				
214	519	KETOROLAC TABLETS DT 10 MG	10's	167,000				
215	520	MEFENAMIC ACID 500 MG+ PARACETAMOL 325 MG TABLETS	10's	140,000				
216	521	TRAMADOL TABLETS SR 100 MG	10's	18,000				
217	522	ALFACALCIDOL TABLETS 0.25 MG	10's	30,000				
218	523	NAPROXEN TABLETS IP 500 MG	15's	49,000				
219	524	LIDOCAINE INJECTION IP 2 %W/V	30 ML VIAL	96,000				
220	525	DICLOFENAC 1.16 w/w+ LINCEED OIL3% w/w+ METHYL SALICYLATE 10% w/w+MENTHOL 5% w/w GEL	30 GM	1,207,000				

Signature: _____

Date Place: _____

Name: _____

Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
221	526	CHLORPHENIRAMINE 4 MG+ CODEINE 10 MG/5 ML SYRUP	100 ML	1,675,000				
222	527	AMMONIUM CHLORIDE 50 MG+ CHLORPHENIRAMINE MALETAE 2.5 MG+ DEXTROMETHORPHAN 5 MG+ GUAIFENESIN 50 MG / 5ML SYRUP	100 ML	258,000				
223	528	PARACETAMOL 500 MG+ PHENYLEPHRINE 10 MG+ CHLORPHENIRAMINE 2 MG TABLETS	10's	792,000				
224	529	LEVOSALBUTAMOL 1.25 MG+ IPRATROPIUM 500 MG RESPULES	5 ML	1,360,000				
225	530	FORMOTEROL 6 MG+ BUDESONIDE 200 MG ROTACAP	30's	89,000				
226	531	GUAIFENESIN 100 MG+ TERBUTALINE 2.5 MG+ BROMHEXINE 8 MG /10 MLSYRUP	100 ML	196,000				
227	532	SALMETEROL 50 MG+ FLUTICASONE 250 MG ROTACAP	30's	47,000				
228	533	BROMHEXINE 4 MG+ DEXTROMETHORPHAN 5 MG+ AMMONIUM CHLORIDE 50 MG /5 ML SYRUP	100 ML	206,000				
229	534	LEVOSALBUTAMOL 200 MG + BECLOMETHASONE 100 MG ROTACAP	30's	357,000				
230	535	TERBUTALINE 2.5 MG + BROMHEXINE 8 MG /10 ML SYRUP	100 ML	192,000				
231	536	PROMETHAZINE 1.5 MG + PHOLCODINE CITRATE 1.5 MG /5ML LINCTUS	60 ML	151,000				
232	537	SALBUTAMOL 1 MG+ AMBROXOL HYDROCHLORIDE 15 MG/5 ML SYRUP	100 ML	548,000				
233	538	THEOPHYLLINE TABLETS 400 MG	10's	91,000				
234	539	ACETYLCYSTEINE TABLETS 600 MG	10's	49,000				
235	540	LEVOSALBUTAMOL 2.5 MG+ BUDESONIDE 2.5 MG REPSULE	5 ML	209,000				
236	541	ACEBROPHYLLINE CAPSULES 100 MG	10's	165,000				

Signature: _____

Date Place: _____

Name: _____

Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
237	542	SODIUM CHLORIDE 0.65% w/v NASAL DROPS	20 ML	258,000				
238	543	MENTHOL CINNAMON and PINE OIL SOFT CAPSULES	10's	128,000				
239	544	FLUTICASONE RESPULE 0.5 MG/2ML	2 ML	117,000				
240	555	DOXOFYLLINE TABLETS IP 400 MG	10's	275,000				
241	556	MONTELUKAST 10 MG + FEXOFENADINE 120 MG TABLETS	10's	147,000				
242	557	TIOTROPIUM ROTOCAP 18 MCG	15's	23,000				
243	558	FLUTICASONE 30 MG+ AZELASTINE 70 MCG NASAL SPRAY	8 ML	13,000				
244	559	SALBUTAMOL 2MG + THEOPHYLLINE 100 MG TABLETS	30's	285,000				
245	560	FLUTICASONE PROPIONATE 0.5 MG PER PUFF NASAL SPRAY	120 MD	16,000				
246	561	LEVOSALBUTAMOL 1 MG/5ML SYRUP	100 ML	137,000				
247	562	LORATIDINE TABLETS BP 10 MG	10's	78,000				
248	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML	28,000				
249	564	FORMOTEROL 12 MG + TIOTROPIUM 18 MG ROTOCAP	15's	19,000				
250	565	CICLESONIDE 400 MCG+ FORMOTEROL 12 MCG + TIOTROPIUM 18 MCG ROTOCAP	15's	6,000				
251	566	IPRATROPIUM 250 MCG/ML I:SOLUTION	15 ML	26,000				
252	567	SALBUTAMOL 100 MCG + IPRATROPIUM 20 MCG /PUFF INHALER	100 MD	7,000				
253	568	SALMETEROL 50 MG+ FLUTICASONE PROPIONATE 250 MG /PUFF INHALER	100 MD	28,000				
254	569	SILDENAFIL TABLETS IP 50 MG	9's	162,000				
255	570	TADALAFIL TABLETS 20 MG	4's	53,000				
256	571	TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG TABLETS	15's	44,000				

Date Place: _____ Name: _____ Signature: _____
 Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
257	572	COMBINATIONS WITH TETANUS COMPONENT (DIPHTHERIA, TETANUS, PERTUSSIS, POLIOMYELITIS, AND HAEMOPHILUS INFLUENZA) INJECTION	5 ML	40,000				
258	573	MONOCLONAL ANTI-D GAMAGLOBULIN INJECTION 300 MCG	1 ML	11,000				
259	574	VACCINE RABIES INJECTION 2.5 IU	1 ML	93,000				
260	575	VACCINE VARICELLA INJECTION 0.5 ML	5 ML	15,000				
261	576	VACCINE HEPATITIS A INJECTION 80 IU	5 ML	13,000				
262	577	VACCINE STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE INJECTION 0.5 ML	0.5 ML	11,000				
263	578	VACCINE ROTA VIRUS LIVE ORAL	1 ML	20,000				
264	579	CALCIUM PANTOTHENATE 50MG+VIT B12 15 MCG+FOLIC ACID 1.5MG+THIAMINE MONONITRATE 10MG+RIBOFLAVINE 10MG+PYRIDOXINE HCL 3 MG+NIACINAMIDE 100 MG+ASCORBIC ACID 150MG +BIOTIN 100MCG CAPSULES	20's	2,971,000				
265	580	GINSENG VITAMIN A,B,D,E,CARBOHYDRATE, PROTEIN AND MINERALS CAPSULES	10's	451,000				
266	581	CALCIUM CARBONATE 500 MG + CALCITRIOL 0.25 MCG + ZINC 7.5 MG	15's	113,000				
267	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	200 ML	184,000				
268	583	CYPROHEPTADINE TABLETS IP 4 MG	10's	966,000				
269	584	CALCIUM CITRATE MALATE 250 MG , VITAMIN D3 100 IU AND FOLINIC ACID 50 MCG TABLETS	30's	171,000				

Date Place: _____ Name: _____ Designation: _____ Signature: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. Tender Quantity in units	Manufacturing Capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total Value (5X6) in figures
						In figures (in Rs.)	In words	
270	585	VITAMIN D - CHOLECALCIFEROL 60000 IU / 1 GM SACHET	1 SACHET	356,000				
271	586	METHYLCOBALAMIN 1500 MCG, L CARTININE L TARTRATE 500 MG, FOLIC ACIDE 1.5 MG TABLETS	10's	100,000				
272	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS)SYRUP	300 ML	172,000				
273	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's	483,000				
274	589	CALCIUM 500 MG+ CALCITRIOL 0.25 MG TABLETS	15's	43,000				
275	590	VITAMIN A,B COMPLEX,D,E INJECTION	10 ML VIAL	498,000				
276	591	METHYLCOBALAMIN 500 MCG INJECTION	1 ML AMPULE	115,000				
277	592	L-LYSINE + MULTIVITAMINS SYRUP	200 ML	207,000				
278	593	NICOTINAMIDE 200 MG+ FOLIC ACID 15 MG + CYANOCOBALAMIN 0.5 MCG INJECTION	10 ML	109,000				
279	594	GLUCOSE D POWDER	100 GM	22,000				
280	595	THIAMINE 100 MG+ PYRIDOXINE HCl 50 MG + CYANOCOBALAMIN 1000 MCG INJECTION	2 ML	602,000				
281	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15 ML	40,000				
282	597	VITAMIN B6 TABLETS IP 5 MG	10's	147,000				
283	598	PREGABALIN 75 MG+ METHYLCOBALAMIN 1500 MCG TABLETS	10's	120,000				
284	599	PREGABALIN TABLETS 75 MG	10's	120,000				
<p>Note: For combination drugs which are not official in the pharmacopeas, the manufacturer will have to provide the test protocol. *As per stated formulation/combination is fixed but strength may vary</p>								

Date Place: _____ Name: _____ Signature: _____
Designation: _____

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016										
TENDER FOR THE SUPPLY OF MEDICINES REDERENCE BPPI/DRUG/016 DT 28-01-2015								Annexure - XVIII		
Break Up of Landed Price								Ref Clause 5		
Note 1: The firms should indicate breakup prices at column 4 to 6 and 8 to 10 sepraty and wording like "included" should not be substituted for the same as per specifications laid down in relevant pharmacopeias										
Note 2: For combination drugs which are not official in the pharmacopeas, the manufacturer will have to provide the test protocol.										
*As per stated formulation/combination is fixed but strength may vary										
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
(1)	(2)	(3)		(4)	(5)	(6)	(7)	(8)	(9)	(10)
1	5	ASPIRIN TABLETS IP 150 MG	14's							
2	6	DICLOFENAC 50 MG+ PARACETAMOL 325 MG+ CHLORZOXAZONE 500 MG TABLETS	10's							
3	40	AMOXYCILLIN 250 MG+ CLOXACILLIN 250 MG CAPSULES	9's							
4	60	CEFOTAXIME SODIUM 250 MG & SULBACTAM SODIUM 125 MG INJECTION	1 Vial & wfi							
5	83	CIPROFLOXACIN 250 MG+ TINIDAZOLE 300 MG TABLETS	10's							
6	89	CO-TRIMOXAZOLE TABLETS IP (160 MG + 800 MG)	10's							
7	98	NORFLOXACIN 400 MG + TINIDAZOLE 600 MG FILM COATED TABLETS	10's							
8	109	VANCOMYCIN INJECTION IP 500 mg	VIAL & WFI							
9	112	BECLOMETHASONE IP 0.025% w/w+ CLOTRIMAZOLE IP 1% w/w+ GENTAMYCIN IP 0.1% w/w CREAM	15 GM							
10	117	CHLORHEXIDINE MOUTHWASH IP 2 % w/v	160 ML							
11	142	INSULIN INJECTION IP 40 IU/ML (Insulin Human Recombinant)	10 ML VIAL							
12	143	BIPHASIC INSULIN ASPART INJECTION IP 100 IU/ML (30:70)	VIAL							
13	144	METFORMIN HYDROCHLORIDE TABLETS IP SR 1000 MG	10's							
14	153	CISPLATIN INJECTION IP 10 MG	VIAL							
15	165	CIPROFLOXACIN INJECTION IP 2MG/ML	100 ML							
16	170	MANNITOL INJECTION IP 20% w/v	100 ML							
17	172	METRONIDAZOLE INJECTION IP 5 MG / ML	100 ML							

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
18	178	ALBENDAZOLE 400 MG + IVERMECTIN 6 MG TABLETS	1's							
19	181	TRICHOLINE CITRATE 275 MG+ CYPROHEPTADINE HCl 2 MG/5ml SYRUP	200 ML							
20	188	ANTACID TABLETS [DRIED Al(OH) ₃ + Mg(OH) ₂ + SIMETHICONE (250MG + 250MG + 50MG)	10's							
21	191	FAMOTIDINE TABLETS IP 20 MG	10's							
22	192	FAMOTIDINE TABLETS IP 40 MG	14's							
23	196	LACTOBACILLUS SPOROGENES 60 MILLION SPORES TABLETS	10's							
24	208	ONDENSETRON INJECTION IP 2 mg/ml	2 ML							
25	216	RANITIDINE INJECTION IP 50 MG/ 2ML	2 ML							
26	218	RANITIDINE TABLETS IP 300 MG FILM COATED	10's							
27	223	PYRIDOXINE HCl 10 MG+ DOXYLAMINE 10 MG + FOLIC ACID 2.5 MG TABLETS	30's							
28	225	IRON HYDROXIDE POLYMALTOSE COMPLEX EQ TO ELEMENTAL IRON 50 MG+ FOLIC ACID 0.5 MG /15 ML SYRUP	200 ML							
29	230	VITAMIN B COMPLEX WITH ZINC CAPSULES	20's							
30	231	VITAMIN B1 10MG, B2 10 MG, NIACINAMIDE 45 MG, CALCIUM PANTOTHENATE 50 MG, B6 3 MG AND B12 15 MCG TABLETS	10's							
31	232	VITAMIN B-VOMPLEX NFI Syrup	200 ML							
32	235	BUDESONIDE RESPULES 0.5 MG	2 ML							
33	241	COUGH SYRUP DEXTROMETHORPHAN HBR 10 mg+ CPM 10 MG /10 ML SYRUP	100 ml							
34	242	COUGH SYRUP [CPM 3 MG. + ALU.CHL. 110 MG. +SOD. CIT. 46 MG. + MENTHOL 0.9 MG /5 ML]	110 ML							

Signature: _____

Date Place: _____

Name: _____

Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
35	243	COUGH SYRUP [DIPHEN.14 MG. + ALU.CHL.135 MG. + SOD.CIT.57 MG. + MENTHOL 0.9 MG/5ML]	110 ML							
36	244	THEOPHYLLINE 25.3 MG+ ETOPHYLLINE 84.6MG INJECTION 2 ML	2 ML							
37	253	PHENIRAMINE TABLETS IP 25 MG	15's							
38	255	SALBUTAMOL INHALATION IP 100 µg	200 MD							
39	270	ASPIRIN 75 MG + CLOPIDOGREL 75 MG TABLETS	10's							
40	278	FRUSEMIDE INJECTION IP (10 MG/ ML)	2 ML							
41	285	AMLODIPINE 5 MG + LISINOPRIL 5 MG TABLETS	15's							
42	299	TELMISARTAN TABLETS IP 20 mg	10's							
43	302	TRANEXAMIC ACID 500 MG/5 ML	5 ML AMPULE							
44	306	PRIMAQUINE TABLETS IP 15 MG	7's							
45	323	FLUNARZINE TABLETS 10MG	10's							
46	324	FLUNARZINE TABLETS 5MG	10's							
47	327	PHENYTOIN TABLETS IP 100 MG	100's in Bottle							
48	329	PREDNISOLONE TABLETS IP 5 MG	15's							
49	331	THYROXINE SODIUM TABLETS IP 50 µg	10's							
50	334	DEXAMETHASONE INJECTION IP 4 MG/ML	2 ML							
51	338	ATROPINE SULPHATE INJECTION IP 0.6MG/ ML	1 ML							
52	341	CARBOXY METHYL CELLULOSE EYE DROPS IP 0.5% w/v	10 ML							
53	356	LIGNOCAINE INJECTION IP 2% w/v	20 ML VIAL							
54	359	TETANUS VACCINE (Adsorbed) IP	AMP 0.5 ML							
55	360	MIFEPRISTONE TABLETS 200 MG	1's							
56	361	OXYTOCIN INJECTION 5 iu/ ml	1 ML							
57	362	BIPHASIC ISOPHANE INSULIN INJECTION IP 40 IU/ML (50:50)	10 ML VIAL							
58	363	GLARGINE 100 IU INJECTION	CARTRI DGE 3 ML							

Signature:_____

Date Place:_____ Name:_____ Designation:_____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
59	364	GLIMEPIRIDE 2 MG + METFORMIN HYDROCHLORIDE 500 MG TABLETS SR	15's							
60	365	GLICLAZIDE 80 MG + METFORMIN HYDROCHLORIDE TABLETS 500 MG	15's							
61	366	GLIPIZIDE 5 MG + METFORMIN HYDROCHLORIDE 500 MG TABLETS	10's							
62	367	VOGLIBOSE TABLETS IP 0.3 MG	10's							
63	368	GLICLAZIDE TABLETS SR 60 MG	14's							
64	369	ACARBOSE TABLETS IP 50 MG	10's							
65	370	NEUTRAL PROTAMINATED HAGEDORN INJECTION 40 IU	10 ML VIAL							
66	371	VOGLIBOSE TABLETS IP 0.2 MG	10's							
67	372	METFORMIN HYDROCHLORIDE TABLETS IP SR 500 MG	10's							
68	373	ARTESUNATE INJECTION 60 MG	1 ML							
69	374	ARTEMETHER 80 MG + LUMEFANTRINE 480 MG TABLETS	6's							
70	375	QUININE SULPHATE TABLETS IP 300 MG FILM COATED TABLETS	10's							
71	376	IMIPENEM AND CILASTATIN INJ IP (500MG+500MG)	20 ML							
72	377	CLINDAMYCIN CAPSULES IP 300 MG	10's							
73	378	RIFAMPICIN, ISONIAZIDE, ETHAMBUTOL and PYRAZINAMIDE TABLETS IP (450MG+300MG+800MG+750MG) KIT	1's							
74	379	RIFAMPICIN and ISONIAZIDE TABLETS IP (450 MG+300 MG)	10's							
75	380	CLARITHROMYCIN TABLETS IP 500 MG	4's							
76	381	CEFIXIME 200 MG + OFLOXACIN 200 MG TABLETS	10's							
77	382	LINEZOLID TABLETS IP 600 MG	10's							

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
78	383	CEFPODOXIME 200 MG+ CLAVULANIC ACID 125 MG TABLETS	6's							
79	384	ITRACONAZOLE CAPSULES 100 MG	4's							
80	385	CEFIXIME 200 MG + CLAVULANIC ACID 125 MG TABLETS	10's							
81	386	DIETHYLCARBAMAZINE TABLETS IP 50 MG	30's							
82	387	TERBINAFINE 250 MG TABLETS	7's							
83	388	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG and ETHAMBUTOL TABLET IP 800MG	1's							
84	389	PENICILLIN G 400000 IU TABLETS	6's							
85	390	ETHAMBUTOL TABLETS IP 800 MG	10's							
86	391	MOXIFLOXACIN TABLETS 400 MG	5's							
87	392	GRISEOFULVIN TABLETS IP 250 MG	10's							
88	393	ACICLOVIR TABLETS IP 800 MG	5's							
89	394	PYRANTEL PAMOATE ORAL SUSPENSION IP 250 MG/10 ML	10 ML							
90	395	CEFUROXIME 500 MG+ CLAVULANIC ACID 125 MG TABLETS	6's							
91	396	AMPHOTERICIN B INJECTION 50 MG	20 ML							
92	397	OXYTETRACYCLINE CAPSULES IP 250 MG	8's							
93	398	RIFAMPICIN TABLETS IP 450 MG	10's							
94	399	RIFAMPICIN, ISONIAZIDE and PYRAZINAMIDE TABLETS IP (100MG+50MG+300MG)	10's							
95	400	KETOCONAZOLE TABLETS IP 200 MG	10's							
96	401	AMOXYCILLIN and POTASSIUM CLAVULANATE TABLETS IP (250MG+150MG)	6's							
97	402	AMOXYCILLIN and POTASSIUM CLAVULANATE TABLETS IP (875MG+125MG)	6's							
98	403	CLINDAMYCIN INJ IP 300 MG/2 ML	2 ML							

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
99	404	LINEZOLID INFUSION 300 MG/200 ML	200 ML							
100	405	OFLOXACIN INFUSION IP 200 MG /100 ML	100 ML							
101	406	ACICLOVIR INTRAVENOUS INFUSION IP 500 MG/VIAL	VIAL							
102	407	IVERMECTIN TABLETS 12 MG	10's							
103	408	BENZYLPENICILLIN INJECTION IP 0.6 MILLION UNITS	VIAL							
104	409	BENZYLPENICILLIN INJECTION IP 1.2 MILLION UNITS	VIAL							
105	410	TRASTUZUMAB INJECTION 400 MG	1's							
106	411	BEVACIZUMAB INJECTION 100 MG	1's							
107	412	AZATHIOPRINE TABLETS IP 50 MG	10's							
108	413	METHOTREXATE TABLETS IP 7.5 MG	10's							
109	414	TRANEXAMIC ACID 500 MG+ MEFENAMIC ACID 250 MG TABELTS	10's							
110	415	GLYCERYL TRINITRATE TABLETS IP 250 µg	25's							
111	416	PRAZOSIN TABLETS IP 5 MG	15's							
112	417	TELMISARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	15's							
113	418	ROSUVASTATIN TABLETS IP 20 MG	10's							
114	419	HEPARIN SODIUM 50 IU/20 GM OINTMENT	20 GM							
115	420	ATORVASTATIN 10 MG+ CLOPIDOGREL 75 MG TABLETS	10's							
116	421	NEBIVOLOL HYDROCHLORIDE TABLETS IP 5 MG	10's							
117	422	TORSEMIDE TABLETS 10 MG	15's							
118	423	BISOPROLOL TABLETS 5 MG	10's							
119	424	CARVEDILOL TABLETS IP 3.125 MG	10's							
120	425	DILTIAZEM TABLETS IP SR 90 MG	10's							
121	426	ACENOCOUMAROL TABLETS IP 2 MG	30's							
122	427	S-AMLODIPINE TABLETS IP 2.5 MG	10's							
123	428	DIGOXIN TABLETS IP 250 µg	10's							

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
124	429	ATORVASTATIN 10 MG+ FENOFIBRATES 160 MG TABLETS	15's							
125	430	AMIODARONE TABLETS IP 200 MG	10's							
126	431	RAMIPRIL and HYDROCLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	10's							
127	432	OLMESARTAN TABLETS 40 MG	10's							
128	433	ISOSORBIDE-5-MONONITRATE TABLETS IP 30 MG	30's							
129	434	PROPRANOLOL TABLETS IP 40 MG	10's							
130	435	ROSUVASTATIN 10 MG + FENOFIBRATES 160 MG TABLETS	10's							
131	436	TELMISARTAN 40 MG+ CHLORTHALIDONE 12.5 MG TABLETS	10's							
132	437	NIFEDIPINE SUSTAINED RELEASE TABLETS IP 20 MG	10's							
133	438	INDAPAMIDE TABLETS IP 1.5 MG	10's							
134	439	OLMESARTAN 40 MG + HYDROCLORTHIAZIDE 12.5 MG TABLETS	10's							
135	440	METOPROLOL 50 MG + AMLODIPINE 5 MG TABLETS	7's							
136	441	LOSARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	10's							
137	442	FENOFIBRATE CAPSULES IP 150 MG	10's							
138	443	ISOSORBIDE DINITRATE TABLETS IP 5 MG	50's							
139	444	ENALAPRIL 10 MG + HYDROCLORTHIAZIDE 25 MG TABLETS	30's							
140	445	OLMESARTAN 5 MG+ AMLODIPINE 20 MG TABLETS	10's							
141	446	AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE 12.5 MG TABLETS	10's							
142	447	MOXONIDINE TABLETS 0.3 MG	10's							
143	448	AMLODIPINE 5 MG+ RAMIPRIL 5 MG TABLETS	10's							
144	449	SPIRONOLACTONE TABLETS IP 25 MG	15's							
145	450	LABETALOL TABLETS IP 100 MG	10's							

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
146	451	STREPTOKINASE INJECTION IP 1500000 IU	10 ML							
147	452	WARFARIN TABLETS IP 5 MG	10's							
148	453	BISOPROLOL 5 MG+ HYDROCHLOROTHIAZIDE 6.25 MG TABLETS	10's							
149	454	VALSARTAN TABLETS IP 80 MG	10's							
150	455	VERAPAMIL TABLETS IP 80 MG	10's							
151	456	ATORVASTATIN TABLETS IP 40 MG	10's							
152	457	TORSEMIDE TABLETS 20 MG	10's							
153	458	LABETALOL INJECTION IP 5 MG/ML	4 ML VIAL							
154	459	HYDROQUINONE 2 MG + MOMETASONE 0.1 MG+ TRETINOIN 0.025 % CREAM	20 GM							
155	460	TERBINAFINE 1 MG + CLOBETASOL 0.05 MG + OFLOXACIN 0.75 MG + ORNIDAZOLE 2 % w/w CREAM	15 GM							
156	461	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM							
157	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12w/w+3% w/w)	30 GM							
158	463	MUPIROCIN OINTMENT IP 2 % w/w	5 GM							
159	464	DICYCLOMINE 10 MG + PARACETAMOL 325 MG + TRAMADOL 50 MG CAPSULES	8's							
160	465	DOMPERIDONE 30 MG+ PANTOPRAZOLE 40 MG CAPSULES	10's							
161	466	URSODEOXYCHOLIC ACID TABLETS IP 300 MG	10's							
162	467	DICYCLOMINE 10 MG+ MEFENAMIC ACID 250 MG TABLETS	10's							
163	468	ENTEROGERMINA ORAL SUSPENSION 200 MILLION/ 5 ML	100 ML							
164	469	HEPATIC PROTECTORS SYRUP	200 ML							
165	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ML							

Signature:_____

Date Place:_____ Name:_____ Designation:_____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
166	471	OXETACAIN 10 MG+ ALUMINIUM 291 MG + MAGNESIUM 98 MG /5 ML GEL	200 ML							
167	472	DOMPERIDONE 30 MG+ ESOMEPRAZOLE 40 MG CAPSULE	10's							
168	473	LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40 MG CAPSULE	10's							
169	474	DOXYLAMINE 10 MG+ PYRIDOXINE HCl 10 MG TABLETS	30's							
170	475	SUCRALFATE SUSPENSION 500 MG/5L	200 ML							
171	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG /5ML EMULSION	200 ML							
172	477	CLIDINIUM 2.5 MG+ CHLORDIAZEPOXIDE 5 MG TABLETS	15's							
173	478	SODIUM PICOSULPHATE 10 MG TABLETS	10's							
174	479	TRICHOLINE CITRATE 550 MG + SORBITOL 7.15 MG SYRUP/5 ML	200 ML							
175	480	LEVOSULPIRIDE 75 MG+ ESOMEPRAZOLE 40 MG CAPSULES	10's							
176	481	RIFAXIMIN TABLETS BP 40 MG	10's							
177	482	LEVOSULPIRIDE 75 MG+ RABEPRAZOLE 20 MG 5 TABLETS	10's							
178	483	LOPERAMIDE CAPSULES IP 2 MG	10's							
179	484	ESOMEPRAZOLE TABLETS IP 40 MG	10's							
180	485	PROMETHAZINE TABLETS IP 25 MG	10's							
181	486	PANCREATIN 170 MG+ DIMETHICONE 80 MG TABLETS	10's							
182	487	DICYCLOMINE 10 MG + DIMETHICONE 40 MG /5 ML SUSPENSION	30 ML							
183	488	LANSOPRAZOLE CAPSULES IP 15 MG	10's							
184	489	SULFASALAZINE TABLETS BP 1000 MG ENTERIC COATED	10's							
185	490	SIMETHICONE 15 ML DROPS	15 ML							
186	491	ITOPRIDE TABLETS 50 MG	10's							

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
187	492	SULFASALAZINE TABLETS BP 500 MG ENTERIC COATED	10's							
188	493	ISPAGHULA HUSK IP 50 GM	50 GM							
189	494	ISPAGHULA HUSK IP 100 GM	100 GM							
190	495	FERROUS AMMONIUM CITRATE 160 MG + CYANO COBALAMINE 7.5 MCG + FOLIC ACID 0.5 MG/15ML SYRUP	200 ML							
191	496	DYDROGESTERONE TABLETS IP 10 MG	10's							
192	497	MIFEPRISTONE 200 MG+ MISOPROSTOL 200 MG TABLETS	1's							
193	498	FERROUS ASCORBATE TABLETS 1.1 MG	10's							
194	499	NORETHISTERONE TABLETS IP 5 MG	10's							
195	500	LEVO-THYROXINE TABLETS IP 100 MCG	100's in Bottle							
196	501	BETAMETHASONE TABLETS IP 0.5 MG	20's							
197	502	DEFLAZACORT TABLETS 6 MG	6's							
198	503	METHYL PREDNISOLONE ACETATE INJECTION IP 40 MG/ML	8 ML							
199	504	NANDROLONE DECANOATE INJECTION IP 25MG/ML	2 ML							
200	505	CARBIMAZOLE TABLETS IP 10 MG	100's in Bottle							
201	506	LEVO-THYROXINE TABLETS IP 50 MCG	100's in Bottle							
202	507	CARBIMAZOLE TABLETS IP 5 MG	10's							
203	508	LEVETIRACETAM TABLETS 500 MG	10's							
204	509	HYDROXYCHLOROQUINE TABLETS IP 200 MG	10's							
205	510	PARACETAMOL 325 MG+ TRAMADOL 37.5 MG TABLETS	10's							
206	511	PARACETAMOL TABLETS IP 650 MG	15's							
207	512	ACECLOFENAC 100 MG + PARACETAMOL 325 MG + SERRATIOPEPTIDASE 15 MG TABLETS	10's							
208	513	PIROXICAM CAPSULES IP 20 MG	10's							
209	514	CHYMOTRYPSIN + TRYPSIN (1:6) TABLETS 100K AU	20's							

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
210	515	MEFENAMIC ACID SUSPENSION 100 MG/5 ML	60 ML							
211	516	ACECLOFENAC TABLETS SR 200 MG	10's							
212	517	THIOLCHOLCHICOSIDE 4 MG+ ACECLOFENAC 100 MG TABLETS	10's							
213	518	BACLOFEN TABLETS IP 10 MG	10's							
214	519	KETOROLAC TABLETS DT 10 MG	10's							
215	520	MEFENAMIC ACID 500 MG+ PARACETAMOL 325 MG TABLETS	10's							
216	521	TRAMADOL TABLETS SR 100 MG	10's							
217	522	ALFACALCIDOL TABLETS 0.25 MG	10's							
218	523	NAPROXEN TABLETS IP 500 MG	15's							
219	524	LIDOCAINE INJECTION IP 2 %W/V	30 ML VIAL							
220	525	DICLOFENAC 1.16 w/w+ LINCEED OIL3% w/w+ METHYL SALICYLATE 10% w/w+MENTHOL 5% w/w GEL	30 GM							
221	526	CHLORPHENIRAMINE 4 MG+ CODEINE 10 MG/5 ML SYRUP	100 ML							
222	527	AMMONIUM CHLORIDE 50 MG+ CHLORPHENIRAMINE MALETAE 2.5 MG+ DEXTROMETHORPHAN 5 MG+ GUAIFENESIN 50 MG / 5ML SYRUP	100 ML							
223	528	PARACETAMOL 500 MG+ PHENYLEPHRINE 10 MG+ CHLORPHENIRAMINE 2 MG TABLETS	10's							
224	529	LEVOSALBUTAMOL 1.25 MG+ IPRATROPIUM 500 MG RESPULES	5 ML							
225	530	FORMOTEROL 6 MG+ BUDESONIDE 200 MG ROTACAP	30's							
226	531	GUAIFENESIN 100 MG+ TERBUTALINE 2.5 MG+ BROMHEXINE 8 MG /10 MLSYRUP	100 ML							
227	532	SALMETEROL 50 MG+ FLUTICASONE 250 MG ROTACAP	30's							

Signature:_____

Date Place:_____ Name:_____ Designation:_____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
228	533	BROMHEXINE 4 MG+ DEXTROMETHORPHAN 5 MG+ AMMONIUM CHLORIDE 50 MG /5 ML SYRUP	100 ML							
229	534	LEVOSALBUTAMOL 200 MG + BECLOMETHASONE 100 MG ROTACAP	30's							
230	535	TERBUTALINE 2.5 MG + BROMHEXINE 8 MG /10 ML SYRUP	100 ML							
231	536	PROMETHAZINE 1.5 MG + PHOLCODINE CITRATE 1.5 MG /5ML LINCTUS	60 ML							
232	537	SALBUTAMOL 1 MG+ AMBROXOL HYDROCHLORIDE 15 MG/5 ML SYRUP	100 ML							
233	538	THEOPHYLLINE TABLETS 400 MG	10's							
234	539	ACETYLCYSTEINE TABLETS 600 MG	10's							
235	540	LEVOSALBUTAMOL 2.5 MG+ BUDESONIDE 2.5 MG REPSULE	5 ML							
236	541	ACEBROPHYLLINE CAPSULES 100 MG	10's							
237	542	SODIUM CHLORIDE 0.65% w/v NASAL DROPS	20 ML							
238	543	MENTHOL CINNAMON and PINE OIL SOFT CAPSULES	10's							
239	544	FLUTICASONE RESPULE 0.5 MG/2ML	2 ML							
240	555	DOXOFYLLINE TABLETS IP 400 MG	10's							
241	556	MONTELUKAST 10 MG + FEXOFENADINE 120 MG TABLETS	10's							
242	557	TIOTROPIUM ROTOCAP 18 MCG	15's							
243	558	FLUTICASONE 30 MG+ AZELASTINE 70 MCG NASAL SPRAY	8 ML							
244	559	SALBUTAMOL 2MG + THEOPHYLLINE 100 MG TABLETS	30's							
245	560	FLUTICASONE PROPIONATE 0.5 MG PER PUFF NASAL SPRAY	120 MD							
246	561	LEVOSALBUTAMOL 1 MG/5ML SYRUP	100 ML							
247	562	LORATIDINE TABLETS BP 10 MG	10's							
248	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML							

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
249	564	FORMOTERAL 12 MG + TIOTROPIUM 18 MG ROTOCAP	15's							
250	565	CICLESONIDE 400 MCG+ FORMOTEROL 12 MCG + TIOTROPIUM 18 MCG ROTOCAP	15's							
251	566	IPRATROPIUM 250 MCG/ML I:SOLUTION	15 ML							
252	567	SALBUTAMOL 100 MCG + IPRATROPIUM 20 MCG /PUFF INHALER	100 MD							
253	568	SALMETEROL 50 MG+ FLUTICASONE PROPIONATE 250 MG /PUFF INHALER	100 MD							
254	569	SILDENAFIL TABLETS IP 50 MG	9's							
255	570	TADALAFIL TABLETS 20 MG	4's							
256	571	TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG TABLETS	15's							
257	572	COMBINATIONS WITH TETANUS COMPONENT (DIPHTHERIA, TETANUS,PERTUSSIS,POLIOM YELITIS, AND HAEMOPHILUS INFLUENZA) INJECTION	5 ML							
258	573	MONOCLONAL ANTI-D GAMAGLOBULIN INJECTION 300 MCG	1 ML							
259	574	VACCINE RABIES INJECTION 2.5 IU	1 ML							
260	575	VACCINE VARICELLA INJECTION 0.5 ML	5 ML							
261	576	VACCINE HEPATITIS A INJECTION 80 IU	5 ML							
262	577	VACCINE STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE INJECTION 0.5 ML	0.5 ML							
263	578	VACCINE ROTA VIRUS LIVE ORAL	1 ML							
264	579	CALCIUM PANTOTHENATE 50MG+VIT B12 15 MCG+FOLIC ACID 1.5MG+THIAMINE MONONITRATE 10MG+RIBOFLAVINE 10MG+PYRIDOXINE HCL 3 MG+NIACINAMIDE 100 MG+ASCORBIC ACID 150MG +BIOTIN 100MCG CAPSULES	20's							

Signature:_____

Date Place:_____ Name:_____ Designation:_____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
265	580	GINSENG VITAMIN A,B,D,E,CARBOHYDRATE, PROTEIN AND MINERALS CAPSULES	10's							
266	581	CALCIUM CARBONATE 500 MG + CALCITRIOL 0.25 MCG + ZINC 7.5 MG	15's							
267	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	200 ML							
268	583	CYPROHEPTADINE TABLETS IP 4 MG	10's							
269	584	CALCIUM CITRATE MALATE 250 MG , VITAMIN D3 100 IU AND FOLINIC ACID 50 MCG TABLETS	30's							
270	585	VITAMIN D - CHOLECALCIFEROL 60000 IU /1 GM SACHET	1 SACHET							
271	586	METHYLCOBALAMIN 1500 MCG, L CARTININE L TARTRATE 500 MG, FOLIC ACIDE 1.5 MG TABLETS	10's							
272	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS)SYRUP	300 ML							
273	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's							
274	589	CALCIUM 500 MG+ CALCITRIOL 0.25 MG TABLETS	15's							
275	590	VITAMIN A,B COMPLEX,D,E INJECTION	10 ML VIAL							
276	591	METHYLCOBALAMIN 500 MCG INJECTION	1 ML AMPULE							
277	592	L-LYSINE + MULTIVITAMINS SYRUP	200 ML							
278	593	NICOTINAMIDE 200 MG+ FOLIC ACID 15 MG + CYANOCOBALAMIN 0.5 MCG INJECTION	10 ML							
279	594	GLUCOSE D POWDER	100 GM							
280	595	THIAMINE 100 MG+ PYRIDOXINE HCl 50 MG + CYANOCOBALAMIN 1000 MCG INJECTION	2 ML							
281	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15 ML							
282	597	VITAMIN B6 TABLETS IP 5 MG	10's							
283	598	PREGABALIN 75 MG+ METHYLCOBALAMIN 1500 MCG TABLETS	10's							

Signature: _____

Date Place: _____ Name: _____ Designation: _____

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Freight and Insurance charges	Total landed price (4+5+6)	Rate of		Cen. Excise Duty Applicable (Y/N)
								CST %	VAT %	
284	599	PREGABALIN TABLETS 75 MG	10's							

Date Place: _____ Name: _____ Designation: _____ Signature: _____